FLOW CYTOMETRY REPORT TEMPLATES
Andy Nguyen, M.D. / UT-Medical School at Houston, Pathology/ Last Revision on: 2/27/2017

 

 

NO MALIGNANCY

No abnormal immunophenotypes

1. LN: normal

88. LN: normal, 2 gates

5. PB: normal

44. PB, 2 GATES, normal

42. PERIPHERAL BLOOD: NORMAL (SW)

34. BM: normal, 2 gates

48. Non Clinical Documentation (EMR template)

 

 

No evidence of leukemia

7. PB: normal, no myeoblasts

19. PB: no evidence of acute leukemia

105. PB: no evidence of leukemia in pediatric blood smear

103. BM: no residual lymphoblastic leukemia

108. AML-M5a: s/p chemo, no residual leukemia, 3 gates

20. BM: no residual APL

100. Bone marrow: no residual AML

172. Bone marrow: No MRD in AML, s/p Chemo

156. BM: No residual myeloblasts, CML with accelerated phase, s/p chemo

 

No evidence of MDS

148. BM: no evidence of MDS

151. BM: a subpopulation  of cells with low side-scatter signal but no evidence of MDS

 

Polyclonal plasma cells

3. BX: 10% polyclonal plasma cells

86. BM: 1% polyclonal plasma cells

180. BM: 7% polyclonal plasma cells

 

Other non-malignant cases

147. Right tonsil biopsy: follicular hyperplasia (92% B lymphocytes)

136. PB: Predominant T cells with no abnl immunophenotypes

4. PB: normal (sK/L markers not dome)

10. PB: B cells markedly decreased (<1%), due to Rituximab treatment

13. PB: premature infant with myeloblasts

17. BM: negative for NK cell lymphoma and T-LGL

144. Pleural fluid: a small number of NK cells

18. BAL: no evidence of malignancy

94. BAL: DESCRIPTIVE REPORT, NO SPECIFIC FINDINGS

36. BM: no evidence of abnormal mast cells

46. BM: negative for Mast Cells and Blasts

47: Lung Mass: normal flow results with cHL

107. Mediastinal mass: no evidence of lymphoblastic lymphoma or thymoma

102. PB: markedly decreased B cells, presumably due to chemotherapy with Rituximab

 

MPN and MDS

125. PB: CML with 3% blasts

118. PB: CML in accelerated phase, 15% myeloblasts

11. PB: myeloproliferative disorder

122. PB: Transient Abnormal myelopoiesis in Down syndrome, 20% blasts

123. BM: MPN/MDS with 7% blasts

82. BM: RAEB-1

83. BM: RAEB-2

112. BM: CMML, 3 gates, no transformation to acute leukemia

160. BM:CMML-accelerated phase

149.BM: suggestive of MDS

185. BM: refractory anemia with excess blasts-type I (RAEB-I)

 

AML

6. BM: AML

67. PB: AML, 2 gates

111. BM: AML, 2 gates, aberrant expression of CD19, TdT

139. BM: AML with aberrant expression of CD2, CD7

62. BM: APL

109. PB: APL

99. PB: AML-M4

73. PB: AML-M4, 2 gates

92. PB: AML-M4, 3 gates

75. BM: AML-M4, residual leukemia, s/p therapy

84. PB: AML-M5a

101. CSF: AML-M5a relapse

57. BM: AML-M6

93. BM: AML-M6, pure erythroid leukemia, 3 gates

24. PB: AML-M7

78. PB: 0.2% myeloblasts

166. BM: AML-M2 transformed to AML-M6

168. BM: AML-M4 or M5

 

LYMPHOBLASTIC

53. PB: PRECURSOR B LYMPHOBLASTIC LEUKEMIA

132. BAL: B lymphoblastic leukemia

61. PB: precursor B lymphoblastic leukemia, 2 gates, no evidence of AML-M7

97. BM: B lymphoblastic leukemia, Minimal Residual Disease

64. PB: PRECURSOR B LYMPHOBLASTIC LEUKEMIA WITH sKAPPA RESTRICTION

51. Pleural fluid: PRECURSOR T LYMPHOMA

163. PB: B lymphoblastic leukemia

164. Pelvic mass: B lymphoblastic lymphoma

184. Mediastinal mass: T lymphoblastic lymphoma

187. BM: Residual B lymphoblastic leukemia (8% leukemic cells)

 

PLASMA CELL

14. Lytic lesion FNA: plasmacytoma

161. Spine lesion: plasma cell malignancy

138. RIB LESION: 1% monoclonal plasma cells (numerous plasma cells in H&E)

140. Soft tissue, mandible: artifactual loss of plasma cells (numerous plasma cells in H&E)

2. BM: 1% monoclonal plasma cells 

25. BM: plasma cell myeloma

59. BM: PLASMA CELL MYELOMA

33. BM: plasma cell myeloma / false-negative cytoplasmic light-chain restriction

 

 

B CELL

 

CLL/SLL/BML

15. PB: CLL

21. PB: CLL with atypical FMC7, bright CD20

69. PB: CLL with negative CD20

141. PB: CLL with pos ZAP70

9. LN: SLL

49. Aortic wall: SLL, no surface light chains, cytoplasmic lambda light-chain restriction

116. SLL: polyclonal with surface K/L and monoclonal with cytoplasmic K/L

165. BM: Benign monoclonal lymphocytosis (BML)

181. PB: CLL

 

DLBCL variants

38. Chest Wall BX: DLBCL

124. T6 LESION, DLBCL

143. Retroperitoneal mass: DLBCL, low cell viability

40. CHEST WALL MASS: DLBCL with no light-chain restriction due to necrosis

41. LEFT SCAPULAR NODULE FNA: DLBCL with lack of KAPPA/LAMBDA

68. BM: DLBCL, S/P chemotherapy with decreased B cells

8. LN: mediastinal B cell lymphoma

128. Thymus: PMLBCL

30. Pleural fluid: primary effusion lymphoma

150. Supraclavicular lymph node biopsy: plasmablastic lymphoma

 

 

Follicular lymphoma

26. BM: FL, grade 1

29. Pelvic mass: FL, Gr 1

91. LN, CORE BX: FL, GR 1/3

114. BM: FL with no definitive kappa/lambda restriction

 

 

DLBCL /  follicular lymphoma

23. LN: FL / DLBCL

79. BM: FL / DLBCL

 

Other B cell lymphomas

43. LUNG MASS (ASPIRATE): MALT

104. Retroperitoneal mass: MZL

119. Cervical LN: MZL

60. BM: Splenic MZL

95. BM: Burkitt Lymphoma

96. LN: Burkitt Lymphoma

98. BM: Lymphoplasmacytic lymphoma

152. BM: lymphoplasmacytic lymphoma

63. PB: PLL vs. MCL

70. PB: PLL vs. MCL

179. PB: MCL

175. Lacrimal gland: mantle cell lymphoma

72. BM: B-cell lymphoma, 20% B cells (small lymphocytes)

174. Bone marrow: hairy cell leukemia

177. Pleural fluid: PEL

178. Bone marrow: CD5-positive low grade leukemia/lymphoma

182. PB: CD5-pos Lymphoproliferative Disorder

 

T and NK CELL

81. Axillary mass: PTCL, NOS

131. Mesenteric LN: PTCL, NOS

133. LN: ALCL

89. LN: AITCL

12. (L) Neck mass FNA: T-cell neoplasm

90. Tonsil: T cell lymphoma

16. Spleen: T cell lymphoma, low viability

66. PB: SS in patient with MF

71. BM: NK/T LYMPHOMA

159. BM: NK/T Lymphoma

37. BM: chronic LPD of NK cells

117. PB: chronic lymphoproliferative disorder of NK cells vs. aggressive NK cell leukemia

126. PB: 14% NK cells in PB, reactive condition vs. NK cell lymphoproliferative disorder

162. PB: aggressive NK cell leukemia vs. chronic NK cell lymphoproliferative disorder

170. PB:  T-LGL

186. BM: T-Cell LGL

 

 

MISCELLANEOUS

Hematogones

35. BM: hematogones

154. BM: 20% hematogones in 15 y/o male with neuroblastoma

137. BM: normal, 2 gates- APL in remission with 3% hematogones

110. BM: 5% hematogones: APL, s/p chemo

167. BM: 2% hematogones, no residual APL

173. Bone marrow: 2% hematogones with 1.5% myeloblasts

 

Non-hematopoietic tumors

113. Nasal mass: non-hematopoietic malignancy, CD56-pos (small blue cell tumor)

142. Nasal mass; pos CD56, negative for NK/T lymphoma

22. LN: non-hematopoietic malignancy (rhabdomyosarcoma)

58. LN: non-hematopoietic tumor (small cell carcinoma)

115. Biopsy containing carcinoma, no lymphocytes

127. LN: Squamous Cell Carcinoma, less than 1% lymphocytes

121. LN: small-cell carcinoma, CD56-pos; 3% lymphocytes

54. LUNG MASS: less than 1% LYMPHOCYTES, CANNOT R/O CA (keratin-pos)

28. Mediastinal mass: thymoma

145. Mediastinal mass: thymoma or thymic hyperplasia

106. Mediastinal mass: thymocytes (in thymoma or thymic hyperplasia)

183. LN: non-hematopoietic tumor

 

Atypical immunophenotypes

129. EPIDURAL MASS: HIGH CD4/CD8

27. BAL: partial loss of CD7 in T cells / low cell viability

39. CSF- Partial loss of CD7

80. PB: T CELLS WITH LOSS OF CD7

176. Lung biopsy: Reactive, low CD4 in HIV patient, aberrant loss of CD7

77. BM: a small population of atypical B cells with CD10 expression, and lack of surface light chains

31. Pleural fluid: atypical CD38&CD56 cells / suboptimal sample

 

Nondiagnostic

74. BM: False Negative for Burkitt lymphoma due to suboptimal aspirate

52. Mediastinal mass: NECROSIS, NON-DIAGNOSTIC

55. LN: non-diagnostic due to low cell viability

120. LN: non-diagnostic with DLBCL due to poor viability of lymphoma cells

87. Chest tube fluid: non-diagnostic due to non-viable sample

56. Aortic mass: normal profile, accuracy is compromised by low viability

45. BAL: low cell count and low viability

157. BAL: low number of lymphocytes and a high H/S ratio

50. QNS for flow analysis

135. QNS for lymphocytes(or a non-lymphoma tumor)

65. CSF: QNS

32. BM: non-diagnostic due to uneven distribution of lymphoma cells (FL, Gr 1)

85. Paraspinal mass: non-diagnostic for plasmacytoma due to sampling

146. Right thigh mass biopsy: T cell/histiocyte-rich large B cell lymphoma (flow is non-diagnostic)

153. LN: cHL (flow is not diagnostic)

171. Mediastinal mass: high CD4/CD8 in cHL

155. BM: AML with only 1% myeloblasts in aspirate due to dilution

158. Very few leukocytes in sample

169. CSF: Many B lymphoblasts, negative by flow, s/p chemo

 

 

 

 

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

1. LN: normal

Immunophenotyping of cervical lymph node biopsy by flow cytometry shows a T cell population (about 76% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 23% of the cells analyzed) that is negative for CD5, CD10, CD56, no surface light-chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT 88188                         

 

 

2. BM: 1% monoclonal plasma cells 

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell  population with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, also no surface light-chain restriction. Plasma cells account for about 1% of the cells analyzed and show cytoplasmic kappa light chain restriction. Impression: presence of monoclonal plasma cells (1%) in bone marrow.

CPT 88189   

 

3. BX: 10% polyclonal plasma cells

Immunophenotyping of sinus biopsy by flow cytometry shows a T cell  population with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, also no surface light-chain  restriction. Plasma cells account for about 10% of the cells analyzed and show no evidence of cytoplasmic light chain restriction. Impression: no evidence of monoclonal B cells or monoclonal plasma cells by flow cytometry.

CPT 88189                                                        

 

4. PB: normal

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a T cell population (about 62% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 35% of the cells analyzed) that is negative for CD5, CD10, CD16, and CD56.

CPT 88187

 

 

5. PB: normal

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a T cell population (about 58% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 35% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT 88189      

 

6. BM: AML

Immunophenotyping of bone marrow aspirate by flow cytometry shows a predominant myeloblast population that is positive for CD34, CD13, CD33 (partial, and dim signal for CD33), CD4, and HLA-DR.  These blasts are negative for CD14, CD16, CD56, CD19, CD10, CD117, and TdT. Impression: these

findings are consistent with acute myeloid leukemia.

CPT 88189 

 

7. PB: normal, no myeoblasts

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 50% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 45% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  The analyzed cells are negative for CD34, CD13, and CD33. Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT 88189                                                                    

 

8. LN: mediastinal B cell lymphoma

Immunophenotyping of supraclavicular lymph node by flow cytometry shows a T cell population (about 25% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 25% of the cells analyzed) that is negative for CD5, CD10, CD23, no expression of  surface-light chains (neither kappa nor lambda). These B cells have large nuclear size (based on forward-scatter signal) and are positive for CD19, CD20, CD22, FMC7. The analyzed cells are negative for TdT. Impression: these results are consistent with a B-cell lymphoma, most likely mediastinal  (thymic) B cell lymphoma (a subtype of diffuse large B cell lymphoma). Definitive diagnosis would require additional data (morphology and immunoperoxidase stains on the biopsy).

CPT 88189

 

9. LN: SLL

Immunophenotyping of parotid lymph node by flow cytometry shows a T cell    population (about 17% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 88% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, surface   kappa light chain restriction (dim signal). These B cells are negative for  CD10, and CD38. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results are consistent with a B-cell lymphoma, most likely small lymphocytic lymphoma. Definitive diagnosis would be based on correlation with morphology.                             

CPT 88189  

 

10. PB: B cells markedly decreased (<1%), due to Rituximab treatment

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a T cell population (about 80% of the cells analyzed) with low CD4/CD8 ratio (0.25), no aberrant expression of T cell markers. The B cells are markedly decreased (<1%), presumably due to Rituximab treatment in this patient with autoimmune disease.

CPT 88188

 

 

11. PB: myeloproliferative disorder

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, also no surface    light-chain restriction.  A small myeloblast population (about 2% of the cells  analyzed) is found of which the results are shown in this panel. These blasts   are positive for CD34, CD13, and CD33. Review of the peripheral blood smear shows normochromic normocytic RBCs, thrombocytosis (Plt count 545k), marked leukocytosis (WBC 87k) with left shift including 4% blasts. Impression: the immunophenotyping results by flow cytometry, together with morphological findings, are consistent with a myeloproliferative disorder. Further testing  for bcr-abl and JAK2 mutations (by PCR using peripheral blood in EDTA tubes) is suggested if clinically indicated.

CPT 88189  

 

12. (L) Neck mass FNA: T-cell neoplasm

Immunophenotyping of (L) neck mass aspirate by flow cytometry shows a normal subpopulation of small lymphocytes consisting of T cell and B cells (results not shown in panel). A subpopulation of lymphocytes with large nuclear size  (based on forward-scatter signal) shows expression of CD2, CD3, CD4, CD5, and   CD7. No aberrant expression or aberrant loss of T cell markers is found. These large CD4-pos cells account for about 20% of the cells analyzed.  Impression:  expression of T cell markers in this lymphocytic population with large nuclei  is suggestive of a T cell neoplasm.                                             

CPT 88188      

 

13. PB: premature infant with myeloblasts

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a mixture of T cells and B cells with normal marker profile (results not shown  in this panel). A small population of myeloblasts (about 3% of the cells analyzed) is found that is positive for CD13, CD33, and negative for CD34. Impression: a small population of myeloblasts is found with flow cytometry. Review of peripheral blood smear shows 8% blasts in this 6 week-old infant (born at 35 wk gestation) with URI.                                       CPT 88189         

 

14. Lytic lesion FNA: plasmacytoma

Immunophenotyping of lytic lesion by flow cytometry shows a large monoclonal plasma cell population that is positive for CD56, CD38, cytoplasmic Kappa light-chain restriction. These plasma cells are negative for CD19. Impression: these results are consistent with a plasma cell dyscrasia.

CPT 88189  

 

15. PB: CLL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 95% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, surface  lambda light chain restriction (dim signal). These B cells are negative for CD10, FMC7, and CD38. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in peripheral blood, are consistent with chronic lymphocytic leukemia (CLL).

CPT 88189

 

 

16. Spleen: T cell lymphoma, low viability

Immunophenotyping of the spleen biopsy by flow cytometry shows a T cell population with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, no surface light-chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry. Note: results are compromised by low viability of the cells  analyzed (ranging from 34% to 76%). Please refer to surgical pathology report for final diagnosis.                                                        

CPT 88188    

 

 

17. BM: negative for NK cell lymphoma and T-LGL

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell  population (about 87% of the cells analyzed) with partial loss of CD7 and CD4/CD8 ratio of 0.5, a small B cell population (about 4% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain  restriction. No prominent CD2(+)/CD56(+) population is found. Impression: (1) no evidence of NK cell leukemia or T cell large granular lymphocytic leukemia, (2) partial loss of CD7 in T cells can be seen in benign conditions (examination of lymphocytes in bone marrow shows normal morphology). 

CPT 88188                                                                                                                                          

                          

 

18. BAL: no evidence of malignancy

Immunophenotyping of BAL specimen by flow cytometry shows a leukocyte population that is negative for B cell and T cell markers. Microscopic  examnination of the BAL sample shows that the majority of the cells are macrophages which correspond to these flow cytometry results. The small subpopulations of B cells and T cells show no abnormal immunophenotypes.  Impression: no evidence of malignancy with histological and flow cytometric findings.

CPT 88188  

 

19. PB: no evidence of acute leukemia

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 73% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 25% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. The following markers are negative for the cells analyzed: CD13, CD33, CD34, CD64, TdT, and CD117. Impression: no abnormal immunophenotypes are found with flow cytometry. Especially, no evidence of acute leukemia.

CPT 88189   

 

20. Bone marrow: no residual APL

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 78% of the cells analyzed) with no aberrant loss or aberrant  expression of T cell markers, a B cell population (about 6% of the cells analyzed) with normal marker profile.  A small number of normal myeloblasts   (<1%) is found. No residual leukemic cells are detected [pretreatment profile:   CD13(+), CD33(+), CD34(-), CD64(+), HLA-DR(-)].  Impression: no residual leukemic population is found with flow cytometry.

CPT 88189 

 

21. PB: CLL with atypical FMC7, bright CD20

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an  abnormal B cell population (about 87% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD22, CD23, CD38, FMC7, surface and  cytoplasmic lambda light chain restriction (dim signal). These B cells are negative for CD10. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results are most compatible with chronic lymphocytic leukemia (CLL). There are some atypical findings in this case including abundant cytoplasm of the malignant cells as seen in peripheral blood smear, atypical expression of FMC7, and bright signal for CD20. Due to these unusual features, mantle cell lymphoma with leukemic presentation cannot   be completely ruled out. Further testing for t(11 ; 14) by FISH is suggested.  Peripheral blood sample (green top tube) can be submitted for this test.  

CPT 88189     

 

22. LN: non-hematopoietic malignancy (rhabdomyosarcoma)

Immunophenotyping of submandibular lymph node aspirate by flow cytometry shows a T cell population (about 29% of the leukocytes analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 58% of the leukocytes analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Impression: no abnormal immunophenotypes are found in the leukocytes with flow cytometry. However, most of the cells in the sample (>95%) are not leukocytes (negative for CD45) and they do not express any markers in this panel. These cells are also negative for Cytokeratin by flow cytometry. Morphological findings from lymph node aspirate are consistent with malignancy. Further workup on excisional lymph node biopsy is currently pending.           

CPT 88188    

 

23. LN: FL / DLBCL

Immunophenotyping of the (R) inguinal lymph node biopsy by flow cytometry shows a T cell population (about 8% of the cells analyzed) with no aberrant   loss or aberrant expression of T cell markers, a prominant B cell population  (about 92% of the cells analyzed) that is positive for CD19, CD20, CD22, CD10, FMC7, surface lambda light chain restriction. These B cells are negative for CD5, and CD23. These B cells have intermediate-large nuclear size (based on forward-scatter signal). Impression: these results are consistent with a B-cell lymphoma.  Please refer to surgical pathology report HS-8-2741 (dated 4/25/08) for full details of final diagnosis [Diffuse large B-cell lymphoma (70%) and follicular lymphoma, grade 3/3 (30%), indicating transformation of follicular lymphoma to diffuse large B-cell lymphoma].                            

CPT 88189

 

 

24. PB: AML-M7

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a myeloblast population that is positive for CD34, CD13, CD33, CD117, HLA-DR, CD41a (86% of the blasts), and CD61 (78% of the blasts).  These blasts are negative for CD14, CD16, CD56, CD19, CD20, CD10, CD64, and TdT. Impression: these findings, together with morphological finding of 21% blasts in peripheral blood,                                 

are consistent with acute megakaryoblastic leukemia (AML-M7).

CPT 88189   

 

 

25. BM: plasma cell myeloma

Immunophenotyping of bone marrow aspirate by flow cytometry in gate 1 shows a T cell population (about 60% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 27% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction.  Analysis of cells gated for CD38 positivity shows a large monoclonal plasma cell population that is positive for cytoplasmic Kappa light-chain restriction. These plasma cells are partially positive for CD56 and negative for CD19. Impression: these results, together with the finding of 30% plasma cells in bone marrow, are consistent with plasma cell myeloma.

CPT 88189

 

26. BM: FL, grade 1

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 35% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a prominent B cell population  (about 57% of the cells analyzed) that is positive for CD19, CD20, CD22, CD10, FMC7, surface kappa light chain restriction. These B cells are negative for CD5, and CD23. These B cells small nuclear size (based on forward-scatter signal). Impression: these results are consistent with follicular B-cell lymphoma. 

CPT 88189

 

27. BAL: partial loss of CD7 in T cells / low cell viability

Immunophenotyping of BAL specimen by flow cytometry shows a T cell population (about 95% of the cells analyzed) with partial loss of CD7 and low CD4/CD8 ratio (0.4), and a small B cell population (less than 1% of the cells analyzed). Only 46% of the cells analyzed are viable. Impression: partial loss of CD7 in T cells can be seen in benign conditions. Accuracy of this study is also compromised by low viability of the sample.

CPT 88188                                                                                                                                           

 

28. Mediastinal mass: thymoma

Immunophenotyping of mediastinal mass biopsy by flow cytometry shows a predominant T cell population with small nuclear size (based on forward-scatter signal) with co-expression of CD2, CD3, CD4, CD8, CD5, CD7, and TdT.  Smear pattern in scattergrams is observed for CD3, CD4, and CD8. The B cells only account for only 2% of the cells analyzed.  Impression:  The results are most compatible with thymocytes in thymoma.                                              

CPT 88189

 

29. Pelvic mass: FL, Gr 1

Immunophenotyping of presacral pelvic mass by flow cytometry shows an abnormal B cell population that is positive for CD19, CD20, CD22, CD10, CD22, surface  lambda light chain restriction, and also cytoplasmic lambda light chain  restriction. These B cells are CD45-down regulated (weaker CD45 signal than normal lymphocytes). Impression: these results are consistent with a B-cell lymphoma. Positivity for CD10 suggests follicular origin. 

CPT 88189

 

30. Pleural fluid: primary effusion lymphoma

Immunophenotyping of pleural fluid by flow cytometry shows a T cell population with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, also no surface light-chain restriction. An abnormal population of cells (approximately 6% of the cells analyzed) shows positivity for CD38, CD45, and CD56. These cells are negative for T cell markers (CD2, CD3, CD4, CD8, CD5, CD7) and B cell markers (CD19, CD20).  They show neither surface nor cytoplasmic light chain restriction.  Impression: these results, together with morphological findings, are most compatible with primary effusion (B cell) lymphoma.

CPT 88189

 

31. Pleural fluid: atypical CD38&CD56 cells / suboptimal sample

Immunophenotyping of pleural fluid by flow cytometry shows a T cell population (about 60% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 20% of the cells analyzed) that is negative for CD5, CD10, also no surface light-chain restriction. An

atypical population of cells (approximately 6% of the cells analyzed) shows positivity for CD38, and CD56. These cells are negative for T cell markers (CD2, CD3, CD4, CD8, CD5, CD7) and B cell markers (CD19, CD20).  They show neither surface nor cytoplasmic light chain restriction. Impression: a small population of cells with atypical marker pattern. A definitive diagnosis cannot be rendered with a margin of error due to the small number of cells detected (6%). Further sample collection for flow cytometry analysis is suggested.

CPT 88189   

 

32. BM: non-diagnostic due to uneven distribution of lymphoma cells (FL, Gr 1)

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 61% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 9% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry.  Note: these findings are not diagnostic since the aspirate does not contain sufficient number of malignant cells due to uneven distribution of lymphoma cells in bone marrow. Please refer to bone marrow report HB-8-70 (6/10/08) for full details.

CPT 88189      

 

 

33. BM: plasma cell myeloma / false-negative cytoplasmic light-chain restriction

Immunophenotyping of bone marrow aspirate by flow cytometry shows a normal T cell population (about 85% of the lymphocytes analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 10%  of the lymphocytes analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  An abnormal plasma cell population is detected that is positive for CD38, and CD56. These plasma cells are negative for CD19. The plasma cells do not demonstrate cytoplasmic light-chain restriction.  Note that serum protein immunofixation in this patient (6/12/08) shows monoclonal IgG-kappa.  This false-negative finding (cytoplasmic light-chain restriction by flow cytometry) is most likely due to background stain artifacts.  However, the other marker results (CD38-positive, CD56-positive, CD19-negative) are sufficiently diagnostic of monoclonal plasma cells. Impression: the immunophenotype results, together with morphological findings in bone marrow (report HB-08-71, 6/13/08), are consistent with plasma cell myeloma

CPT 88189      

 

 

34. BM: normal, 2 gates

Immunophenotyping of bone marrow lymphocytes (Gate 2) by flow cytometry shows a T cell population (about 51% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 14% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Analysis of the cells in the blast area (Gate 1) shows fewer than 2% blasts (of the bone marrow cells) that are positive for CD13 and CD33.  Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT 88189      

 

35. BM: hematogones

Immunophenotyping of bone marrow aspirate by flow cytometry shows a lymphocytic population (Gate #1) with normal immunophenotype.  A small population of hematogones is found in blast gate (Gate #2) which express CD45 (down-regulated), CD34, CD10 (bright signal intensity), CD19, CD20, CD38 (bright signal intensity), and TdT.  They are negative for CD99 and CD58. Scattergrams of CD34 and CD20 (CD20 paired with CD10) show a smear-out pattern of CD34 and CD20 indicating a continuum of maturation, consistent with that of hematogones.  The hematogones account for approximatedly 2-4% of the bone marrow cells. Note that hematogones may be increased in bone marrow of very young patients. Impression: no evidence of acute leukemia.

CPT 88189 

 

36. BM: no evidence of abnormal mast cells

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell  population (about 80% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 11% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. No prominent CD2(+)/CD25(+) or CD2(+)/CD117(+) population is found. Impression: No abnormal immunophenotypes are seen. Particularly, no evidence of abnormal mast cells is found.

CPT 88189                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

 

37. BM: chronic LPD of NK cells

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell  population (about 42% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 12% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Approximately 50% of the lymphocytes express a marker profile consistent with NK cell lineage (positive for CD2, CD56, CD16; and negative for CD5, CD3, CD57). These NK cells account for about 8-10% of the bone marrow cells. Impression: increased number of NK cells in bone marrow. Please refer to bone marrow report (HB-8-100) for full discussion and correlation.

CPT 88189

 

38. Chest Wall BX: DLBCL

Immunophenotyping of the left chest wall lesion by flow cytometry shows a small T cell population (about 31% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a predominant B cell population (about 60% of the cells analyzed) that is positive for CD19, CD20, CD22, and surface kappa light-chain restriction.  They are negative for CD5, CD10, and CD23. These B cells have large nuclear size (based on forward-scatter signal). Impression: these results are consistent with a B-cell lymphoma.  The flow cytometric immunophenotype, morphology, and immunostain findings are consistent with diffuse large B-cell lymphoma (please refer to report HS-8-6344 for details).

CPT 88189

 

39. CSF- Partial loss of CD7

Immunophenotyping of CSF specimen by flow cytometry shows a T cell population (about 98% of the cells analyzed) with partial loss of CD7, and a small B cell population (less than 1% of the cells analyzed).

Impression: partial loss of CD7 in T cells can be seen in benign conditions. However, a T-cell lymphoproliferative disorder cannot be ruled out. Correlation with morphology is suggested.  

CPT 88188

 

40. CHEST WALL MASS: DLBCL with no light-chain restriction due to necrosis

Immunophenotyping of left chest wall mass by flow cytometry (in gate#2) shows a small T cell population (about 3% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a predominent B cell population (about 91% of the cells in gate#2) that is negative for CD5, CD10, and CD23, These B cells are positive for CD20, CD22, and CD19. The ratio of surface light chains (kappa/lambda) is  2:1. The ratio of cytoplasmic kappa/lambda is also 2:1

 

 

41. LEFT SCAPULAR NODULE FNA: DLBCL with lack of KAPPA/LAMBDA

Immunophenotyping of the left scapular nodule FNA by flow cytometry (in gate#2) shows a small T cell population (about 5% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a predominant B cell population (about 86% of the cells in gate#2) that is negative for CD5, CD10, CD23, and TdT. These B cells are positive for CD20, CD22, and CD19. These B cells do not express surface kappa nor lambda light chains. The size of the malignant cells is large based on forward-scatter signal. Lymphocytes in gate#1 show immunophenotypic profile consistent with normal B cells and T cells.  The ratio of CD4/CD8 is low (0.1).  Impression: with lack of both surface kappa and lambda light chains in a B cell population in the sample, the flow cytometric findings are consistent with a B-cell lymphoma. The current results (flow cytometry and morphology in FNA smears) are consistent with recent diagnosis of diffuse large B-cell lymphoma (left chest wall biopsy, report HS-8-6707, issued on 10/7/08).

CPT 88189

 

42. PERIPHERAL BLOOD: NORMAL (SW)

Flow cytometric immunophenotyping of peripheral blood, selectively gated using CD45 versus side scatter, discloses a CD45 bright lymphoid population dominated by phenotypically normal T lymphocytes (67%) and CD16/56 positive NK-like cells (13%).  The B lymphocytes (20%) show no discernible aberrant coexpression; light chain expression is polytypic.  Selective gating of the CD45 intermediate "blast" region of the histogram (data not shown) reveals a heterogeneous myeloid population, comprising 2% of analyzed events.  CD34 positive cells within this gate comprise less than 1% of events.  There is no diagnostic immunophenotypic evidence of a lymphoproliferative disorder or abnormal myeloblast proliferation in this specimen.  Clinical and morphologic correlation is required for definitive evaluation.

CPT 88189

 

 

43. LUNG MASS (ASPIRATE): MALT

Immunophenotyping of lung mass aspirate by flow cytometry shows a small T cell population (about 20% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers.  An abnormal B cell population (about 79% of the cells analyzed) is found that is positive for CD19, CD20, CD22, surface kappa light chain restriction. These B cells are negative for CD5, CD10, and CD23. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in lung mass aspirate and biopsy, are most consistent with MALT lymphoma.

CPT 88189

 

44. PB, 2 GATES, normal

Immunophenotyping of peripheral blood leukocytes by flow cytometry in gate #1 shows a T cell population (about 78% of the cells analyzed) with low CD4/CD8 ratio (0.1), no aberrant loss or aberrant expression of T cell markers, a B cell population (about 6% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Immunophenotyping cells in gate #2 shows a T cell population (about 17% of the cells analyzed) with low CD4/CD8 ratio (0.3), no aberrant loss or aberrant expression of T cell markers, a B cell population (about 80% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry

CPT 88189

 

45. BAL: low cell count and low viability

Immunophenotyping of the BAL sample by flow cytometry shows a T cell population (about 73% of the cells analyzed) with normal CD4/CD8 ratio (1.2), a small B cell population (about 3% of the cells analyzed). Lymphocytes account for only 1% of the cells in the sample. Impression: results are not diagnostic due to the low number of lymphocytes in the sample, also low viability of the cells analyzed (45%).           

CPT 88187    

 

46. BM: negative for Mast Cells and Blasts

Immunophenotyping of bone marrow aspirate cells (in gate #1) by flow cytometry shows a T cell population (about 35% of the cells analyzed) with no aberrant loss or aberrant  expression of T cell markers, a B cell population (about 31% of the cells analyzed) with normal marker profile.  Analysis of cells in the blast area (gate #2) shows less than 3% blasts (positive for CD13, CD33, and CD117). Analysis of cells with high side-scatter signal (granulocytes in gate #3) shows no evidence of abnormal mast cells (with expression for CD2, CD25, and CD117).  Impression: no evidence of acute myeloid leukemia or mastocytosis.

CPT:88189

 

47: Lung Mass: normal flow results with cHL

Immunophenotyping of right lung mass biopsy by flow cytometry shows a T cell population (about 76% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 26% of the cells analyzed) that is negative for CD5, CD10, CD23, no surface light-chain restriction.

Impression: no abnormal immunophenotypes are found with flow cytometry. Note that classical Hodgkin lymphoma cannot be ruled out with flow cytometry testing. Please refer to surgical pathology report (HS-8-7588, issued on 11/10/08) for full details.

CPT:88189

 

 

48. Non Clinical Documentation

CPT:88189

Immunophenotyping performed and interpreted at Memorial Hermann Hospital. Some of the tests in this panel were developed and their performance characteristics determined by Memorial Hermann Hospital Laboratory.  They have not been cleared or approved by the U. S. Food and Drug Administration.  The FDA has determined that such clearance or approval is not necessary.  These tests are used for clinical purposes. They should not be regarded as investigational or for research.  This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform highly-complexity clinical testing.

Teaching Physician Statement

"I have personally reviewed the resident's preliminary interpretation and all specimen preparations and have personally issued this report".

 

 

 

CPT:88189

Immunophenotyping performed at Memorial Hermann Hospital Southwest and interpreted at Memorial Hermann Hospital-TMC.

Some of the tests in this panel were developed and their performance characteristics determined by Memorial Hermann Southwest Hospital Laboratory.  They have not been cleared or approved by the U. S. Food and Drug Administration.  The FDA has determined that such clearance or approval is not necessary.  These tests are used for clinical purposes. They should not be regarded as investigational or for research.  This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform highly-complexity clinical testing.

Teaching Physician Statement

"I have personally reviewed the resident's preliminary interpretation and all specimen preparations and have personally issued this report".

 

49. Aortic wall: SLL, no surface light chains, cytoplasmic lambda light-chain restriction.

Immunophenotyping of the aortic wall biopsy by flow cytometry shows a T cell population (about 31% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 73% of the cells analyzed) that is negative for CD10, CD11c, no expression of  surface light chains (neither kappa nor lambda). These B cells have small nuclear size (based on forward-scatter signal) and are positive for CD5, CD19, CD20, CD22, and CD23, also positive for cytoplasmic lambda light-chain restriction. Impression: these results are most consistent small lymphocytic lymphoma.

CPT:88189

 

 

50. QNS for flow analysis

Flow cytometry analysis shows less than 2% of the cells from the sample expressing lymphocytic markers (CD45, and CD5 or CD20).

The flow cytometry results are non-diagnostic due to the lack of sufficient cells from the sample for analysis.

 

51. Pleural fluid: PRECURSOR T LYMPHOMA

Immunophenotyping of pleural fluid by flow cytometry shows predominant a T cell population (about 95% of all the cells analyzed).  These T cells have small nuclear size (based on forward-scatter signal) and show expression of CD2, CD5, CD7, CD10, CD38, TdT, co-expression of CD4 and CD8. They are negative for CD3.  The analyzed cells are negative for CD19, CD20, CD34, CD13, CD117, and CD33. Review of pleural fluid smear shows a predominant lymphoblast population. Impression: the immunophenotype results and morphology are consistent with precursor T lymphoma.

CPT 88189   

 

   

52. Mediastinal mass: NECROSIS, NON-DIAGNOSTIC

Cell Surface Marker Results

99,000 events were obtained, from which only 206 were CD45-positive (leukocytes)

Interpretation

Immunophenotyping of mediastinal mass by flow cytometry is not diagnostic due to failure to obtain intact lymphocytes for analysis, most likely due to necrosis (see surgical pathology report HS-09-871 for details). 

 

 

53. PB: PRECURSOR B LYMPHOBLASTIC LEUKEMIA

Immunophenotyping of peripheral blood by flow cytometry shows predominant a B cell population (about 80% of all the cells analyzed).  These B cells have small nuclear size (based on forward-scatter signal) and show expression of CD10, CD19, CD38, HLA-DR, and TdT.  They are partially positive for CD20 and negative for CD2, CD3, CD4, CD8, CD5, CD7, CD56, CD34, CD13, CD117, and CD33. Review of peripheral blood smear shows a predominant lymphoblast population. Impression: the immunophenotype results and morphology are consistent with precursor B lymphoblastic leukemia. Dr. Rodriguez was notified of the findings on 2/11/09.

CPT 88189   

                                                            

54. LUNG MASS: less than 1% LYMPHOCYTES, CANNOT R/O CA (keratin-pos)

Flow cytometry analysis shows less than 1% of the cells from the lung biopsy sample expressing leukocytic markers (CD45).  These cells are mostly T cells (positive for CD3 and CD5) accounting for about 70% of the lymphocytes. A smaller number of lymphocytes (18%) are B cells (positive for CD20). The lymphocytes are negative for CD16 and CD56. Up to 19% of all the non-leukocyte cells are positive for cytokeratin. Impression: the flow cytometry results show no evidence of lymphoma. Carcinoma cannot be ruled out with the presence of cytokeratin-positive cells. Morphological correlation is needed.

CPT:88189

 

55. LN: non-diagnostic due to low cell viability

Immunophenotyping of lymph node biopsy by flow cytometry shows a T cell population (about 32% of the cells analyzed), and B cell population (60% of the cells analyzed). Only 12% of the cells analyzed are viable.

Impression: non-diagnostic results due to low viability of the sample.

 

56. Aortic mass: normal profile, accuracy is compromised by low viability

Immunophenotyping of aortic mass biopsy in gate #1 by flow cytometry shows a T cell population (about 80% of the cells analyzed), and B cell population (12% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Only 29% of the cells analyzed are viable. Gating of CD38-positive cells show no evince of cytoplasmic light-chain restriction. Immunophenotyping of CD45-negative cells in gate#2 shows no B cells or T cells. Impression: No abnormal immunophenotypes are found with flow cytometry. However, accuracy of this study is compromised by low viability of the sample.

CPT:88189

 

                                                                                                                                         

57. BM: AML-M6

Immunophenotyping of bone marrow leukocytes by flow cytometry in gate #1 shows a T cell population (about 76% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 7% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction.  Immunophenotyping cells in gate #2 (blast area) shows a predominant population of myeloblasts (positive for CD13, and CD33, and CD117). These blasts also show partial aberrant expression of CD7 and CD19.  They are negative for CD34, CD14, CD41, and CD61.

Impression: these findings are consistent with acute myeloid leukemia.  Please refer to bone marrow report HB-9-28 (issued on 3/2/09) for full details.

CPT 88189 

 

58. LN: non-hematopoietic tumor (small cell carcinoma)

Cell Surface Marker Results

6,450 events were obtained, from which only 684 were CD45-positive (leukocytes)

Interpretation

Immunophenotyping of lymph node sample by flow cytometry is not diagnostic due to failure to obtain adequate number of lymphocytes for analysis. This could be due to: (a) lack of intact lymphocytes (due to degeneration) or (b) the lymph node sample contains mostly non-lymphoid tissue. Morphological correlation is needed.

 

59. BM: PLASMA CELL MYELOMA

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 69% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 18% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. A monoclonal  plasma cell population is found with plasma cells that are positive for CD38, cytoplasmic Kappa light-chain restriction. These plasma cells are negative for CD19 and positive for CD56. Patient's bone marrow shows 11% plasma cells, some with immature cytological features. The immunophenotype results, together with the findings of multiple lytic lesions, are consistent with plasma cell myeloma. Impression: plasma cell myeloma

CPT:88189

 

60. BM: Splenic MZL

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 46% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, an abnormal B cell population (about 48% of the cells analyzed) that is positive for CD19, CD20, CD22, surface kappa light-chain restriction. These B cells are negative for CD5, CD10, CD11c, CD25, and CD103. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in bone marrow, are most consistent with marginal-zone lymphoma (see bone marrow report HB-9-32 for full details). Not that hairy cell leukemia is ruled out with negative expression for CD11c, CD25, and CD103.

CPT:88189

 

61. PB: precursor B lymphoblastic leukemia, 2 gates, no evidence of AML-M7

Immunophenotyping of peripheral blood leukocytes by flow cytometry in gate #1shows an abnormal B cell population (about 30% of all the cells analyzed).  These B cells have small-intermediate nuclear size (based on forward-scatter signal) and show expression of CD10, CD19, CD38, HLA-DR, and TdT.  They are partially positive for CD20 and negative for CD2, CD3, CD4, CD8, CD5, CD7, CD56, CD34, CD13, CD117, CD33, CD41 and CD61. Negative findings for CD41 and CD61 rule out acute megakaryoblastic leukemia. Review of peripheral blood smear shows an abnormal blast population.

Immunophenotyping of the cells in gate #2 shows a normal lymphocytic population consisting of B cell and T cells with normal marker profile. Impression: the immunophenotype results and morphology are consistent with precursor B lymphoblastic leukemia. Dr. D. Brown was notified of the findings on 4/2/09.

CPT:88189

 

62. BM: APL

Immunophenotyping of bone marrow aspirate by flow cytometry shows a predominant leukemic cell population in gate#1 that is positive for CD13, CD33. They show partial expression for CD117, CD38, and CD2.  They are negative for CD34, HLA-DR, and TdT. These cells have intermediate granularity (based on side-scatter signal). Immunophenotyping of the cells in gate #2 shows a normal lymphocytic population consisting of B cell and T cells with normal marker profile. Impression: these results, together with morphological findings in bone marrow, are consistent with acute promyelocytic leukemia.

CPT:88189 

 

 

63. PB: PLL vs. MCL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an  abnormal B cell population (about 90% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD11c, CD22, FMC7, surface lambda light-chain restriction (bright signal). These B cells are negative for CD10, CD23, and CD38. These B cells have small-intermediate nuclear size (based on forward-scatter signal).

Impression: these results, together with morphology in peripheral blood smear, suggest prolymphocytic leukemia vs. mantle cell lymphoma with leukemic presentation.  Patient has been scheduled for bone marrow procedure. Further testing for cyclin-D1 by immunohistochemical stain and t(11 ; 14) by FISH are planned for bone marrow for a definitive diagnosis.  Findings were discussed with Dr. Quesada on 4/24/09.

CPT: 88189     

 

 

64. PB: PRECURSOR B LYMPHOBLASTIC LEUKEMIA WITH sKAPPA RESTRICTION

Immunophenotyping of peripheral blood leukocytes by flow cytometry (in gate#1) shows a predominant B cell population (about 30% of all the cells analyzed).  These B cells have small nuclear size (based on forward-scatter signal) and show expression of CD10, CD19, CD20, CD38, HLA-DR, CD34, surface Kappa light-chain restriction, and TdT. They are negative for CD2, CD3, CD4, CD8, CD5, CD7, CD56, CD13, CD117, and CD33. Review of peripheral blood smear shows a large blast population (30% of leukocytes). Lymphocytes in gate#2 show an immunophenotypic profile consistent with normal B cells and T cells. Impression: the immunophenotype results and morphology are consistent with B lymphoblastic leukemia. Dr. Juneja was notified of the findings on 6/11/09.

Note: the finding of surface light-chain restriction is rare in B lymphoblastic leukemia but does not exclude such diagnosis.

CPT:88189   

 

65. CSF: QNS

Specimen Source: CSF

Clinical Information: 74 y/o male

Cell Surface Marker Results: Flow cytometry analysis shows less than 1% of the cells from the sample expressing leukocyte marker (CD45). Interpretation: The flow cytometry results are non-diagnostic (for lymphoma/leukemia) due to the lack of sufficient cells from the sample for analysis.

CPT:88187

 

66. PB: SS in patient with MF

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a predominant T cell population (about 95% of the cells analyzed) with aberrant loss of CD7.  They are positive for CD2, CD3, CD4, and CD5. Less than 1% of the T cells are positive for CD8.  A very small B cell population (less than 1% of the cells analyzed) is found. Impression:  These immunophenotypic results, together with morphological findings of atypical lymphocytes in the peripheral blood of this patient with history of mycosis fungoides, are consistent with Sezary cells in peripheral blood (Sezary Syndrome)

CPT:88189

 

 

67. PB: AML, 2 gates

Immunophenotyping of peripheral blood leukocytes by flow cytometry in gate#2 shows a T cell population (about 62% of the cells in gate#2) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 17% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  A predominant myeloblast population is seen in gate #1(approximatedly 80% of all the cells analyzed). They are positive for CD34, CD13, CD33, CD117, CD4, CD19, CD38, and HLA-DR.  These blasts are negative for CD14, CD16, CD56, CD10, and TdT. Impression: these findings, together with the presence of numerous blasts with auer rods in the peripheral blood, are consistent with acute myeloid leukemia.

CPT:88189

 

68. BM: DLBCL ,S/P chemotherapy with decreased B cells

Immunophenotyping of bone marrow lymphocytes by flow cytometry shows a T cell population (about 91% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (less than 1% of the cells analyzed) that is negative for CD5, and CD10. The lymphocytes have small nuclear size (based on forward-scatter signal). Impression: no abnormal immunophenotypes are found with flow cytometry. The decrease in bone marrow B cells is most likely due to recent chemotherapy.

CPT:88189

 

 

69. PB: CLL with negative CD20

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 88% of the cells analyzed) that is positive for CD5, CD19, CD22, CD23, surface  lambda light chain restriction (dim signal), and cytoplasmic lambda light chain restriction (dim signal). These B cells are negative for CD10, CD20, FMC7, and CD38. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results are consistent with chronic lymphocytic leukemia (CLL). Note that negativity for CD20 in the leukemic cells may be secondary to: (a) aberrant loss of CD20, or (b) effect of Rituximab if patient had been treated with such therapy. Clinical correlation is suggested.

CPT:88189

 

70. PB: PLL vs. MCL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 31% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, an  abnormal B cell population (about 66% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD11c (partial and dim expression), CD22, FMC7, surface kappa light-chain restriction (bright signal). These B cells are negative for CD10, and CD23. These B cells have small-intermediate nuclear size (based on forward-scatter signal). Impression: these results, together with morphology in peripheral blood smear, are consistent with  B-cell lymphoma / leukemia.  Differential diagnosis includes prolymphocytic leukemia vs. mantle cell lymphoma with leukemic presentation.  Bone marrow and lymph node biopsy (if patient has lymphadenopathy) would be needed for definitive diagnosis. Further testing for cyclin-D1 and t(11 ; 14) may be performed on bone marrow and/or lymph node biopsy.     

CPT:88189

 

 

71. BM: NK/T LYMPHOMA

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell  population (about 40% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers. Approximately 41% of the lymphocytes express a marker profile consistent with NK/T cells (positive for CD2, CD56; and negative for CD3, CD7, CD16). Impression: increased number of NK/T cells in bone marrow. This finding is consistent with lymphoma involvement in bone marrow of this patient with recent diagnosis of nasal NK/T cell lymphoma. Please refer to bone marrow report (HB-9-93) for full details.

CPT 88189

 

72. BM: B-cell lymphoma, 20% B cells (small lymphocytes)

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 65% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, an abnormal B cell population (about 20% of the cells analyzed) that is positive for CD19, CD20, CD22, surface lambda light chain restriction. These B cells are negative for CD5, CD10, and CD23.  These B cells small nuclear size (based on forward-scatter signal). Impression: These results are consistent with monoclonal B-cells.   Further lymphoma workup with lymph node biopsy is suggested.

CPT 88189

 

73. PB: AML-M4, 2 gates

Immunophenotyping of peripheral blood leukocytes by flow cytometry in gate#2 shows a T cell population (about 35% of the cells in gate#2) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 55% of the cells in gate#2) that is negative for CD5, CD10, no surface light-chain restriction.  A predominant monocytic population is seen in gate #1(approximately 60% of all the cells analyzed). They are positive for CD4, CD33, CD38, CD56, and HLA-DR.  These cells are negative for CD13, CD34, CD41, CD61, CD117, and TdT. Impression: these findings, together with the presence of numerous monoblasts/ promocytes/ and monocytes in the peripheral blood, are consistent with acute myelomonocytic leukemia.

CPT:88189

 

74. BM: False Negative for Burkitt lymphoma due to suboptimal aspirate

Immunophenotyping of bone marrow lymphocytes (Gate 1) by flow cytometry shows a T cell population (about 72% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 16% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Analysis of the cells in the blast area (Gate 2) shows fewer than 4% blasts (of the bone marrow cells) that are positive for CD13 and CD33.  Impression: no abnormal immunophenotypes are found with flow cytometry. However, this result is not diagnostic due to insufficient number of marrow cells in aspirate (hypocellular aspirate with peripheral blood contamination). Please refer to bone marrow report HB-09-108 for final diagnosis of Burkitt lymphoma.

CPT:88189

 

75. BM: AML-M4, residual leukemia, s/p therapy

Immunophenotyping of bone marrow aspirate by flow cytometry shows an abnormal population in the same position (CD45/SSC scattergram) as the leukemic cells in original bone marrow sample. The leukemic cells are positive forCD13, CD33, CD56, CD38, CD4. They are negative for CD34, CD117. They account for about 20% of the cells analyzed in the sample.

Impression: these findings are consistent with residual leukemia in this patient with prior diagnosis of AML-M4

CPT:88189

 

76. Immunophenotyping of bone marrow aspirate by flow cytometry in gate#1 shows a T cell population (about 98% of the cells analyzed) with no aberrant loss or aberrant  expression of T cell markers, a small B cell population (about 1% of the cells analyzed).  A small number of normal myeloblasts   (<1%) is found in gate#2.

Impression: no residual leukemic population is found with flow cytometry.

CPT 88189 

 

77. BM: a small population of atypical B cells with CD10 expression, and lack of surface light chains

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #1 shows a T cell population (about 57% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 32% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Analysis of cells in gate#2 shows a small atypical B cell population that is positive for CD10, CD19, CD20, CD38, HLA-DR, lack of both surface kappa light chain and lambda light chain. These B cells are CD45-down regulated and negative for CD5. Impression: a small population of atypical B cells in bone marrow with expression of CD10 and lack of surface light chains.

CPT 88189

 

78. PB: 0.2% myeloblasts

Immunophenotyping of peripheral lymphocytes (Gate 1) by flow cytometry shows a T cell population (about 34% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 53% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Analysis of the cells in the blast area (Gate 2) shows less than 0.2% of the leukocytes in peripheral blood with co-expression of CD34, CD13, CD33, and CD117. 

Impression: a small number of myeloblasts is found in peripheral blood (less than 0.2%). Clinical correlation is suggested.

CPT 88189

 

79. BM: FL / DLBCL

Immunophenotyping of bone marrow aspirate in gates #1 and #2 by flow cytometry shows a predominant B cell population  (about 34% of the cells analyzed) that is positive for CD19, CD20, CD22, CD10, and surface lambda light chain restriction. These B cells are negative for CD5, and CD23. These B cells have large nuclear size (based on forward-scatter signal) in gate #2 and small nuclear size in gate #1.

Impression: these results are consistent with a B-cell lymphoma involvement in bone marrow in this patient with follicular lymphoma transformed to diffuse large B-cell lymphoma. 

CPT 88189

 

80. PB: T CELLS WITH LOSS OF CD7

Immunophenotyping of peripheral leukocytes by flow cytometry in gate #2 shows a T cell population (about 20% of all the cells analyzed) with no aberrant loss or aberrant  expression of T cell markers, and a small B cell population (less than 1% of the cells analyzed). Analysis of the lymphocytes in gate #1 shows a T cell population (about 30% of the all the cells analyzed) with loss of CD7, and a small B cell population (less than 1% of the cells analyzed). The T cells are mostly CD8-positive and CD4-negative.

Impression: loss of CD7 in T cells may be seen in benign conditions. However, a T-cell lymphoproliferative disorder cannot be ruled out. Review of peripheral blood smear shows presence of atypical lymphocytes.  Further workup to rule out a T-cell lymphoproliferative disorder is suggested if clinically indicated.  

CPT:88189

 

 

81. Axillary mass: PTCL, NOS

Immunophenotyping of axillary mass by flow cytometry shows an abnormal population of lymphocytes with intermediate-large nuclear size (based on forward-scatter signal). These cells show expression of CD2, CD3, CD4, and  CD7. They also show aberrant loss of CD5.  CD8-positive cells account for less than 3% of the lymphocytes. Impression:  these results, together with morphological findings in biopsy, are consistent with a T-cell lymphoma.                                             

CPT 88189      

 

82. BM: RAEB-1

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #2 shows a normal lymphocytic population (B cell and T cells). Analysis of cells in gate#2 (blast area) shows a myeloblast population that is positive for CD34, CD13, CD33, CD117, CD38, and HLA-DR.  These blasts are negative for CD14, CD56, CD19, CD10, and TdT. They also aberrantly expressed CD5. The blasts account for about 6% of the bone marrow nucleated cells (in line with manual differential). Impression: bone marrow is hypercellular (90%) with presence of dysplastic normoblasts, granulocytes, and megakaryocytes. Myeloblasts are increased at 6%. The flow cytometry results, together with these morphological findings, are consistent with refractory anemia with excess blasts-type 1 (RAEB-1)

CPT 88189 

 

 

83. BM: RAEB-2

Immunophenotyping of bone marrow aspirate by flow cytometry shows a myeloblast population that is positive for CD34, CD13, CD33, CD117, CD38, and HLA-DR.  These blasts are negative for CD45, CD14, CD56, CD19, CD10, and TdT. They also aberrantly expressed CD5. The blasts account for about 12% of the bone marrow nucleated cells (in line with manual differential). Impression: bone marrow is hypercellular (95%) with presence of dysplastic normoblasts and dysplastic megakaryocytes. Myeloblasts are increased at 12%. The flow cytometry results, together with these morphological findings, are consistent with refractory anemia with excess blasts-type 2 (RAEB-2)

CPT 88189 

 

84. PB: AML-M5a

Immunophenotyping of peripheral leukocytes by flow cytometry shows a predominant blast population that is positive for CD34, CD13, CD33, CD4, CD38, and HLA-DR.  These blasts are negative for  CD19, CD10, CD117, and TdT. Impression: these findings, together with morphological findings in peripheral blood smear (88% blasts), are most consistent with acute monoblastic leukemia (AML-M5a).

CPT 88189 

 

85. Paraspinal mass: non-diagnostic for plasmacytoma due to sampling

Immunophenotyping of paraspinal mass leukocytes by flow cytometry shows a T cell population (about 81% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (less than 1% of the cells analyzed). Gating of CD38 is negative for plasma cells. Impression: no abnormal immunophenotypes are found with flow cytometry. Note: histology and immunohistochemistry study of the paraspinal mass are consistent with plasmacytoma (see separate report CA-9-1149). The lack of plasma cells in this flow cytometric analysis indicates normal tissue from the paraspinal mass being submitted for flow cytometry.

CPT:88188

 

86. BM: 1% polyclonal plasma cells

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell  population (about 79% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population consisting of less than 1% of the cells analyzed. Plasma cells account for about 1% of the cells analyzed and show no evidence of cytoplasmic light chain restriction. Impression: no evidence of monoclonal plasma cells by flow cytometry.

CPT 88189  

 

87. Chest tube fluid: non-diagnostic due to non-viable sample

Immunophenotyping of chest tube fluid by flow cytometry shows 50% of the cells being postive for CD45.  However, only 34% of the cells analyzed are viable. The analyzed cells show no expression of T cell markers (CD2, CD3, CD4, CD8, CD5, CD7) or B cell markers (CD19, CD20). Examination of cytospin sample shows non-viable cells and numerous bacteria. Impression: non-diagnostic results due to low viability of the sample.

CPT:88189

 

88. LN: normal, 2 gates

Immunophenotyping of lymph node lymphocytes in gate #2 (small lymphocytes) by flow cytometry shows a T cell population (about 52% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 33% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Analysis of the cells in the gate #1 (a smaller number of lymphocytes with intermediate size) shows a T cell population (about 56% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 20% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT 88189

 

 

89. LN: AITCL

Immunophenotyping of lymph node lymphocytes in gate #2 (small lymphocytes) by flow cytometry shows a T cell population (about 52% of the cells analyzed) with aberrant loss of CD7 (a T-cell marker), a B cell population (about 33% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Analysis of the cells in the gate #1(a smaller number of lymphocytes with intermediate size) shows a T cell population (about 56% of the cells analyzed) also with aberrant loss of CD7, a B cell population (about 20% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Impression: The aberrant loss of CD7 in T-cells is supportive of a T cell lymphoma. Please refer to surgical pathology report HS-09-9079 for full details (angioimmunoblastic T cell lymphoma).   Dr Mathivanan was notified of the findings on 12/3/09.

CPT:88189

 

90. Tonsil: T cell lymphoma

Immunophenotyping of tonsil biopsy by flow cytometry in gate #1 shows a T cell population (about 79% of the cells analyzed in gate #1) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 12% of the cells analyzed in gate #1) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Immunophenotyping cells in gate #2 shows a T cell population (about 78% of the cells analyzed in gate #2) with positivity for CD2 and CD4. They are negative for CD3, CD8, CD5, CD7, and CD56.  In gate #2, there is also a small B cell population (about 4% of the cells analyzed in gate #2).

Impression: the immunophenotype results are consistent with a T-cell lymphoma.

CPT:88189

 

 

91. LN, CORE BX: FL, GR 1/3

Immunophenotyping of retroperitoneal lymph node by flow cytometry shows an abnormal B cell population (about 54% of the lymphocytes analyzed

) that is positive for CD19, CD20, CD22, CD10, and surface lambda light chain restriction. These B cells are negative for CD5, and CD23. These B cells are predominantly small in size (based on forward-scatter signal)

Impression: these results, together with morphological findings in aspirate smear, are consistent with follicular B-cell lymphoma (low grade with predominant centrocytes).

CPT:88189

 

92. PB: AML-M4, 3 gates

Immunophenotyping of bone marrow leukocytes by flow cytometry in gate#3 shows mixture of normal T cells and B cells.  A predominant blast population is seen in gates #1 and gate #2. They are positive for CD13, CD33, CD34, CD117, CD38, CD56, and HLA-DR.  They are also partial positive for CD4 and CD14. These cells are negative for CD2, CD3, CD8, CD5, CD7, CD10, CD19, CD20

Impression: these findings, together with the morphological findings in bone marrow aspirate, are consistent with acute myelomonocytic leukemia.

CPT:88189

 

 

93. BM: AML-M6, pure erythroid leukemia, 3 gates

Immunophenotyping of bone marrow cells by flow cytometry in gate #1 shows a normal monocytic population with expression of CD13, CD33, CD4, and negative for CD34, CD117.  Analysis of cells in gate #2 shows a mixture of normal T lymphocytes and B lymphocytes.  Analysis of cells in gate #3 shows a small myeloblast population (less than 3%) with expression of CD13, CD33, CD117, and CD34.  Analysis of cells with negative CD45 expression shows a prominent normoblast population with expression of glycophorin A.

Impression: these findings, together with morphological findings in bone marrow, are consistent with acute erythroid leukemia.  Please refer to bone marrow report HB-10-26 (issued on 2/5/2010) for full details.

CPT 88189 

 

 

94. BAL: DESCRIPTIVE REPORT, NO SPECIFIC FINDINGS

Immunophenotyping of the BAL sample by flow cytometry shows a T cell population (about 96% of the cells analyzed) with high CD4/CD8 ratio (3.4), and a small B cell population (about 2% of the cells analyzed). Lymphocytes account for about 20% of the cells in the sample.

         

 

95. BM: Burkitt Lymphoma

Immunophenotyping of bone marrow aspirate by flow cytometry shows an abnormal B cell population (about 50% of the lymphocytes analyzed) that is positive for CD19, CD20, CD22, CD10, and FMC7.  The abnormal cells lack both surface kappa and lambda light chains. These B cells are negative for CD5, and CD23. These B cells are predominantly intermediate in size (based on forward-scatter signal)

Impression: these results, together with morphological findings in aspirate smear and biopsy, are consistent with Burkitt lymphoma

CPT:88189

 

96. LN: Burkitt Lymphoma

Immunophenotyping of lymph node biopsy by flow cytometry shows an abnormal B cell population (about 99% of the lymphocytes gated) that is positive for CD19, CD20, CD22, CD10, FMC7, and surface lambda light chain restriction. These B cells are negative for CD5, and CD23. These B cells are predominantly intermediate in size (based on forward-scatter signal)

Impression: these results, together with morphological findings in lymph node biopsy, are consistent with Burkitt lymphoma

CPT:88189

 

 

97. BM: B lymphoblastic leukemia, Minimal Residual Disease

Immunophenotyping of bone marrow leukocytes by flow cytometry in gate #1 shows a mixture of normal T lymphocytes and B lymphocytes.  Analysis of cells in gate #2 shows an abnormal B cell population (about 2-3% of all the bone marrow cells analyzed).  These B cells have intermediate nuclear size (based on forward-scatter signal) and show expression CD19, CD38, HLA-DR, and TdT.  They are partially positive for CD20 and negative for CD10, CD13, CD117, and CD33.  These B cells are in the blast area of the scatter-gram and show intermediate (down-regulated) expression for CD45. This marker profile is found to be similar to that of original diagnostic sample (report GF-9-1168, issued 10/21/2009) which in particular, showed lack of CD10 expression. Note that the lack of CD10 expression and the lack of smear-out pattern of markers rule out the presence of hematogones in the bone marrow.

Impression: the immunophenotype results are consistent with minimal residual disease (2-3% of leukemic cells in this patient with B lymphoblastic leukemia, S/P chemotherapy).

CPT:88189

 

 

98. BM: Lymphoplasmacytic lymphoma

Immunophenotyping of leukocytes in bone marrow aspirate by flow cytometry shows an abnormal B cell population (about 25% of the cells analyzed) that is positive for CD19, CD20, and surface kappa light chain restriction. These B cells are negative for CD5, and CD10. These B cells are predominantly small in size (based on forward-scatter signal).

Analysis of CD38-positive cells shows a small abnormal plasma cell population. These plasma cells are positive for CD56, with cytoplasmic kappa light-chain restriction. They are negative for CD19.

Impression: these results, together with morphological findings in bone marrow, are consistent with lymphoplasmacytic lymphoma in this patient with a history of macroglobulinemia.

CPT:88189

 

99. PB: AML-M4

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a normal lymphoctic population in gate #2 (normal T cell and B cells). Analysis of cells in gate #1 shows a predominant blast population that is positive for CD13, CD33, CD4, CD117, HLA-DR, and partial positivity for CD34. These blasts are negative for CD16, CD56, CD19, CD10, and TdT. Impression: these findings, together with morphology in peripheral blood and bone marrow, are most consistent with acute myelomocytic leukemia (AML-M4).

CPT:88189

 

100. Bone marrow: no residual AML

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #1 shows a T cell  population (about 51% of the cells analyzed) with no aberrant loss or aberrant  expression of T cell markers, a B cell population (about 42% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction. Analysis of cells in gate #2 (blast area)shows a small number of normal myeloblasts   (<1%).

Impression: no residual leukemic population is found with flow cytometry in this patient with history of AML-M5.

CPT 88189

 

101. CSF: AML-M5a relapse

Immunophenotyping of leukocytes in CSF by flow cytometry in both gate #1 and gate #2 shows a predominant blast population that is positive for CD34, CD13, CD14, CD38, and CD117.  These blasts are negative for  CD33, and TdT. The blasts account for more than 80% of cells in the sample. Impression: these findings, together with morphological findings in CSF, are most consistent with relapse of acute monoblastic leukemia (AML-M5a) in this patient with prior diagnosis of AML-M5a.

CPT: 88189 

 

102. PB: markedly decreased B cells, presumably due to chemotherapy with Rituximab

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a T cell population (about 89% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (less than 1% of the cells analyzed). Impression: markedly decreased B cells, presumably due to chemotherapy with Rituximab. Clinical correlation is suggested.

CPT:88188

 

103. BM: no residual lymphoblastic leukemia

Immunophenotyping of bone marrow lymphocytes (Gate #1) by flow cytometry shows a prodominant T cell population (about 89% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a small B cell population (less than 1% of the cells analyzed).  Analysis of the cells in Gate #2 shows normal monocytic cells.  All the analyzed cells are negative for TdT.

Impression: no residual lymphoblastic leukemia is found with flow cytometry.

CPT :88189 

 

104. Retroperitoneal mass: MZL

Immunophenotyping of retroperitoneal mass by flow cytometry shows a T cell population (about 57% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, an abnormal B cell population (about 38% of the cells analyzed) that is positive for CD19, CD20, CD22, surface kappa light-chain restriction. These B cells are negative for CD5, CD10, CD11c, CD23. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in retroperitoneal mass, are most consistent with marginal-zone lymphoma.

CPT :88189 

 

105. PB: no evidence of leukemia in pediatric blood smear

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 76% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 24% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  The analyzed cells are negative for CD34, CD13, CD33, CD117, and TdT. Impression: no abnormal immunophenotypes are found with flow cytometry. Especially, no evidence of leukemia is found.

CPT :88189 

 

106. Mediastinal mass: thymocytes (in thymoma or thymic hyperplasia)  

Immunophenotyping of mediastinal mass biopsy by flow cytometry shows a predominant T cell population with cells ranging from small nuclear size in gate #2 to intermediate size in gate #1 (based on forward-scatter signal). These T cells show co-expression of CD2, CD3, CD4, CD8, CD5, CD7, and TdT.  Smear pattern in scattergrams is observed for CD2, CD3, CD4, and CD8. The B cells only account for only 2% of the cells analyzed. Impression:  The results are most compatible with thymocytes (in thymoma or thymic hyperplasia).   

CPT :88189 

 

107. Mediastinal mass: no evidence of lymphoblastic lymphoma or thymoma

51 y/o female with large mediastinal mass, suspicious for thymoma. Only 5% lymphocytes found with flow

Immunophenotyping of lymph node biopsy by flow cytometry shows a small population of lymphocytes (only 5% of the cells analyzed). They are mostly T cells (89% positive for CD5) and negative for TdT.

Impression: Flow cytometry shows mostly non-lymphocytic cells. No evidence of lymphoblasts or thymocytes in sample.

CPT:88187

 

108. AML-M5a: s/p chemo, no residual leukemia, 3 gates

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #1 shows a T cell population (about 81% of the cells gated) with no aberrant loss or aberrant  expression of T cell markers, a B cell population (less than 1% of the cells gated ).  Analysis of cells in gate #2 shows a small number of normal myeloblasts   (<2% of the cells gated). No residual leukemic cells are detected [pretreatment profile on 6/3/2010: CD13(+), CD33(+), CD117(+), CD4(+)]. Analysis of cells in gate #3 shows normal monocytes. 

Impression: these results indicate no residual leukemic population with flow cytometry.

CPT :88189 

 

109. PB: APL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a predominant leukemic cell population in gate #1 that is positive for CD13, CD33, MPO, CD2, and CD117. The CD33 distribution is bright and homogeneous. The CD13 distribution is heterogenous. The leukemic cells show only partial expression for HLA-DR and CD34.  They are negative for TdT. These cells have intermediate granularity (based on side-scatter signal). Immunophenotyping of the cells in gate #2 shows a normal lymphocytic population consisting of B cell and T cells with normal marker profile.

Impression: these results, together with morphological findings in peripheral blood, are not diagnostic but they are supportive of acute promyelocytic leukemia. Note that FISH and PCR testing for PML/RARA are pending (see separate reports)

CPT :88189 

 

110. Hematogones: APL, s/p chemo

Immunophenotyping of aspirate by flow cytometry shows a lymphocytic population (Gate #1) with normal immunophenotype.  A small population of hematogones is found (Gate #2) which express CD45 (down-regulated), CD34, CD10 (bright signal intensity), CD19, CD20, CD38 (bright signal intensity), and TdT.  They are negative for CD99 and CD58. Scattergrams of CD34 and CD20 (CD20 paired with CD10) show a smear-out pattern of CD34 and CD20 indicating a continuum of maturation, consistent with that of hematogones.  The hematogones account for approximatedly 5% of the bone marrow cells. Hematogones may be increased in regenerating bone marrow as seen in this patient after chemotherapy. Impression: no evidence of residual leukemia by flow cytometry.

CPT :88189 

 

111. BM: AML, 2 gates, aberrant expression of CD19, TdT

Immunophenotyping of bone marrow aspirate by flow cytometry shows a lymphocytic population (Gate #2) with normal immunophenotype for B cells and T cells.  Analysis of cells in Gate #1 shows a predominant myeloblast population that is positive for CD34, CD13, CD33 (partial, and dim signal for CD33), CD117, CD38, and HLA-DR.  These blasts are also partially positive for CD19 and TdT (aberrant expression). They are negative for CD14, CD16, CD56, and CD10.

Impression: these findings are consistent with acute myeloid leukemia. Note that the partial positivity for CD19 and TdT is not adequate to support a diagnosis of mixed phenotype acute leukemia.

CPT:88189 

 

112. BM: CMML, 3 gates, no transformation to acute leukemia

Immunophenotyping of bone marrow leukocytes (Gate 3) by flow cytometry shows a small lymphocytic population consisting of normal B lymphocytes and T lymphocytes. Analysis of cells in the monocytic area (Gate 2) shows a mature monocytic population. Analysis of the cells in the blast area (Gate 1) shows fewer than 5% blasts (of the bone marrow cells) that are positive for CD13, CD33, and MPO.  TdT is negative for all the cells analyzed.

Impression: these immunophenotype results, together with morphological findings, show no evidence of               transformation to acute leukemia.

 

113. Nasal mass: non-hematopoietic malignancy, CD56-pos (small blue cell tumor)

Immunophenotyping of spinal mass biopsy by flow cytometry shows that most of the cells in the sample are not leukocytes (they are negative for CD45) and they do not express any markers for B cells and T cells in this panel. These cells are positive for CD56 by flow cytometry. These cells have large nuclear size compared to that of small lymphocytes (based on forward-scatter signal). Impression: these results are suggestive of small blue cell tumor (such as neuroblastoma, Ewing sarcoma, premitive neuroectodermal tumor, or rhabdomyosarcoma). Correlation with morphology is suggested.

CPT 88189    

 

114. BM: FL with no definitive kappa/lambda restriction

Immunophenotyping of bone marrow aspirate by flow cytometry in gate 2 shows a normal population of B lymphocytes and T lymphocytes. Analysis of cells in gate 1 shows a small T cell population (about 5% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a prominant B cell population (about 76% of the cells analyzed) that is positive for CD19, CD20, CD22, CD10,and FMC7. These B cells are negative for CD5, CD23, and TdT. These abnormal B cells have small nuclear size (based on forward-scatter signal). Surface and cytoplasmic kappa/lambda do not show a definitive restriction pattern. However, this predominant B cell population with negative TdT is monoclonal mature B cells with this marker profile.

Impression: these immunophenotypic results, together with morphological findings, are consistent with B-cell lymphoma involvement in bone marrow, favoring follicular lymphoma.  Note that grading of follicular lymphoma would require examination of primary site of lymphoma (excisional biopsy). Findings were discussed with Dr Gonzales on 9/22/2010.

CPT 88189    

 

115. Biopsy containing carcinoma, no lymphocytes

Flow cytometry analysis shows less than 1% of the cells from the sample expressing leukocytic markers (CD45)

The flow cytometry results are non-diagnostic due to the lack of sufficient lymphocytes from the sample for analysis.  This is most likely due to the tissue sample containing very few lymphocytes.

 

116. SLL: polyclonal with surface K/L and monoclonal with cytoplasmic K/L

Immunophenotyping of the left kidney aspiration by flow cytometry shows an abnormal B cell population (about 91% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, and CD38. Surface kappa and lambda do not show light-chain restriction.  However, cytoplasmic lambda light-chain shows restriction. These B cells are negative for CD10, and TdT. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results are consistent with small lymphocytic lymphoma (SLL) in the left kidney. Note: previous flow cytometry done on lymph node biopsy (collected on 8/25/10) also showed results diagnostic of SLL

 

117. PB: chronic lymphoproliferative disorder of NK cells vs. aggressive NK cell leukemia

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 72% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 1% of the cells gated). Approximately 30% of the lymphocytes express a marker profile consistent with NK cell lineage (positive for CD2, CD16, CD56; and negative for CD3, CD7). Review of peripheral blood smear shows presence of many large-granular lymphocytes.  Impression: increase in NK cells in peripheral blood. This may be associated with chronic lymphoproliferative disorder of NK cells (an indolent disorder), or aggressive NK cell leukemia. Further workup is suggested. Patient's cardiology team was notified of this finding on 10/15/2010 at 14:00.

 

 

118. PB: CML in accelerated phase, 15% myeloblasts

Immunophenotyping of peripheral blood leukocytes by flow cytometry in gate #2 shows a T cell population with no aberrant loss or aberrant expression of T cell markers, a small B cell population that is negative for CD5, CD10, also no surface light-chain restriction.  Analysis of cells in gate #1 (blast area) shows a blast population that is positive for  CD13, MPO, and CD33. They are partially positive for CD34, and CD117. They are also negative for CD4. Review of the peripheral blood smear shows marked leukocytosis with left shift including 15% blasts, basophilia and eosinophilia. Impression: the immunophenotyping results by flow cytometry, together with morphological findings, are most consistent with chronic myelogenous leukemia in accelerated phase.  Result for bcr-abl mutation is pending.

CPT:88189  

 

 

119. Cervical LN: MZL

Immunophenotyping of left neck lymph node aspirate by flow cytometry shows a T cell population (about 13% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, an abnormal B cell population (about 86% of the cells analyzed) that is positive for CD19, CD20, CD22, FMC7, surface lambda light-chain restriction. These B cells are negative for CD5, CD10, CD11c, CD16, CD56, CD23, CD34, and CD103. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in aspirate, are most consistent with a low-grade (indolent) B cell lymphoma, most likely marginal-zone lymphoma.Excisional biopsy with further marker studies are needed for a definitive diagnosis.

CPT:88189

 

120. LN: non-diagnostic with DLBCL due to poor viability of lymphoma cells

Immunophenotyping of the left groin lymph node biopsy by flow cytometry shows a T cell population (about 78% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 24% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction. These lymphocytes have small nuclear size (based on forward-scatter signal).

Impression: no abnormal immunophenotypes are found with flow cytometry.  Note: these findings are not diagnostic due to low viability of large B cell lymphoma in the sample. Please refer to surgical pathology report S10-2902 for full details.

CPT:88189      

 

121. LN: small-cell carcinoma, CD56-pos; 3% lymphocytes

Flow cytometry analysis shows less than 3% of the cells from the lymph node sample expressing leukocytic markers (CD45). Analysis of these cells shows a T cell population (about 51% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 41% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction.  Up to 40% of all the cells in the sample are non-leukocyte cells and are positive for CD56.

Impression: the flow cytometry results show no evidence of lymphoma. Carcinoma (such as small-cell carcinoma) cannot be ruled out with the presence of CD56-positive cells in the non-leukocyte group. Morphological correlation is needed.

CPT:88189      

 

 

122. PB: Transient Abnormal myelopoiesis in Down syndrome, 20% blasts

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a blast population that is positive for CD41 (90% of the blasts), and CD61 (95% of the blasts). These blasts are partially positive for CD13, CD56, and CD117. They are negative for CD34, CD33, HLA-DR, CD14, CD16, CD19, CD10, CD64, and TdT. Impression: these findings, together with morphological finding of 20% blasts in peripheral blood, are consistent with transient abnormal myelopoiesis in Down syndrome in this patient with trisomy 21. Although this disorder has a high rate of spontaneous remission, non-transient acute myeloid leukemia develops later in 20-30% of these cases within 3 years. Close follow-up is suggested. Findings were notified to nurse practitioner Kitty on 12/29/10

CPT:88189   

 

123. BM: MPN/MDS with 7% blasts

Immunophenotyping of bone marrow aspirate by flow cytometry in blast area shows a

myeloblast population that is positive for CD34, CD13, CD4, CD117, and HLA-DR.  These blasts are

negative for CD33, CD56, CD19, CD10, and TdT. The myeloblasts account for 7% of the bone marrow cells.

Impression: these findings are consistent with increase in myeloblasts in bone marrow.

CPT:88189 

 

124. T6 LESION, DLBCL

Immunophenotyping of the T6 lesion biopsy by flow cytometry shows a T cell population (about 5% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a prominant B cell population  (about 94% of the cells analyzed) that is positive for CD19, CD20, CD22, CD10, FMC7, surface lambda light chain restriction. These B cells are negative for CD5, and CD23. These B cells have intermediate-large nuclear size (based on forward-scatter signal). Impression: these results are consistent with a B-cell lymphoma.  Please refer to surgical pathology report HS-11-167 for full details of final diagnosis. 

CPT:88189 

 

125. PB: CML with 3% blasts

Immunophenotyping of peripheral blood leukocytes by flow cytometry in blast area shows a

myeloblast population that is positive for CD13, CD15, and MPO. These blasts are negative for CD33, CD56, CD19, and TdT. The myeloblasts account for less than 10% of the peripheral blood leukocytes.

Impression: these findings are consistent with peripheral blood smear findings of chronic myelogenous leukemia.

CPT:88189 

 

126. PB: 14% NK cells in PB, reactive condition vs. NK cell lymphoproliferative disorder

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a T cell population (about 39% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 46% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction.  There is a small NK cell population (about 14% of the lymphocytes) with expression of CD16, CD56, and negativity for CD3. Impression: presence of a subpopulation of NK cells in peripheral blood (about 14% of the lymphocytes).  This may represent a reactive condition. However, NK cell lymphoproliferative disorder cannot be ruled out. Furher workup is suggested if clinically indicated.

CPT:88189

 

127. LN: Squamous Cell Carcinoma, less than 1% lymphocytes

Immunophenotyping of left neck mass sample by flow cytometry shows less than 1% of the lymphocytes expressing either T cell markers or B cell markers.  This is due to the presence of mostly non-lymphoid tissue in the lymph node (squamous cell carcinoma, please refer to report CA-11-94 for more details).

CPT:88188

 

128. Thymus: PMLBCL

Immunophenotyping of thymic biopsy by flow cytometry shows a T cell population (about 64% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 37% of the cells analyzed) that is negative for CD5, CD10, no expression of  surface-light chains (neither kappa nor lambda). These B cells have intermediate-large nuclear size (based on forward-scatter signal) and are positive for CD19, CD20, CD22, and FMC7. The analyzed lymphocytes (T and B cells) are negative for TdT. Impression: these results are consistent with a B-cell lymphoma, most likely primary mediastinal  (thymic) large B cell lymphoma (a subtype of diffuse large B cell lymphoma). Please refer to surgical pathology report HS-11-1215 for further details.

CPT:88189

 

129. EPIDURAL MASS: HIGH CD4/CD8

Immunophenotyping of epidural mass biopsy by flow cytometry shows a T cell population (about 68% of the cells analyzed) with high CD4/CD8 ratio (10:1); otherwise no aberrant loss or aberrant expression of other T cell markers, a B cell population (about 35% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. All the lymphocytes have small nuclear size (based on forward-scatter signal). Impression: T cell population with a high CD4/CD8 ratio (10:1)

CPT:88189

 

130. BM: CML, no evidence of accelerated phase

Immunophenotyping of bone marrow leukocytes by flow cytometry in gate #1 shows a T cell population (about 80% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 14% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Analysis of cells in the blast area (gate #2, not displayed) shows a myeloblast population that is positive for CD13, CD33, CD34, and CD117.  The myeloblasts account for less than 3% of the bone marrow cells. Impression: these immunophenotypic findings are supportive of the morphological findings of chronic myelogenous leukemia. No evidence of acccelerated phase is found.

CPT:88189

 

131. Mesenteric LN: PTCL, NOS

Immunophenotyping of mesenteric lymph node biopsy by flow cytometry shows a predominant abnormal population of lymphocytes with intermediate-large nuclear size (based on forward-scatter signal). These cells show expression of CD2, CD3 (cytoplasmic), and CD4. They show partial loss of CD7 and CD3 (surface), also aberrant loss of CD5. They are negative for CD8.

Impression: these results, together with morphological findings in biopsy, are consistent with a peripheral T-cell lymphoma.      

CPT:88189

 

132. BAL: B lymphoblastic leukemia

Immunophenotyping of BAL specimen by flow cytometry shows an abnormal B cell population (about 14% of all the cells analyzed).  These B cells have small-intermediate nuclear size (based on forward-scatter signal) and show expression of CD10, CD19, and CD34.  They are negative for CD20, CD2, CD3, CD4, CD8, CD5, CD7, CD56, and MPO. Measurement of TdT is suboptimal (most likely due to low viability of sample at 55%). Impression: the overall immunophenotype results are most consistent with B lymphoblastic leukemic cells in BAL.

CPT:88189

  

133. LN: ALCL

Immunophenotyping of mesenteric lymph node biopsy by flow cytometry shows a predominant abnormal population of lymphocytes with intermediate-large nuclear size (based on forward-scatter signal). These cells show expression of CD2, CD3 (cytoplasmic), and CD4. They show partial loss of CD7 and CD3 (surface), also aberrant loss of CD5. They are negative for CD8. Impression: these results, together with morphological findings in biopsy, are consistent with a T-cell lymphoma.  Please refer to surgical pathology report HS-11-1839 (anaplastic large cell lymphoma) for full details. 

CPT:88189   

 

134. BM: CLL/SLL no surface K/L, cytoplasmic Lambda

Immunophenotyping of bone marrow leukocytes by flow cytometry shows an abnormal B cell population (about 30% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, lack of both surface kappa and lambda light-chains. These B cells show cytoplasmic lambda light-chain restriction. They are negative for CD10, FMC7, and CD38. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in bone marrow, are consistent with chronic lymphocytic leukemia / small lymphocytic lymphoma.

CPT:88189

 

135. QNS for lymphocytes benign tissue (or a non-lymphoma tumor)

Flow cytometry analysis shows less than 1% of the cells from the sample expressing leukocytic marker (CD45). Impression: the flow cytometry results are non-diagnostic for ruling out lymphoma due to the lack of sufficient lymphocytes from the sample for analysis.  This may be seen in benign tissue or a non-lymphoma tumor. Clinical correlation is suggested.

 

136. PB: Predominant T cells with no abnl immunophenotypes

Immunophenotyping of peripheral blood lymphocytes by flow cytometry shows a predominant T cell population (about 92% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (less than 1% of the cells analyzed). The lymphocytes have small nuclear size (based on forward-scatter signal). Impression: a predominant small T cell population with no abnormal immunophenotypes by flow cytometry.

 

137. BM: normal, 2 gates- APL in remission with 3% hematogones

Immunophenotyping of bone marrow lymphocytes (Gate 1) by flow cytometry shows a T cell population (about 72% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 27% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction.  Analysis of the cells in the blast area (Gate 2) shows less than 1% blasts (of the bone marrow cells) that are positive for CD13 and CD33.  A small population of hematogones is also found (Gate #2) which express CD45 (down-regulated), CD34, CD10 (bright signal intensity), CD19, CD20, CD38 (bright signal intensity), and TdT.  They are negative for CD99 and CD58. Scattergrams of CD34 and CD20 (CD20 paired with CD10) show a smear-out pattern of CD34 and CD20 indicating a continuum of maturation, consistent with that of hematogones.   The hematogones account for approximately 3% of the bone marrow cells. Impression: no abnormal immunophenotypes are found with flow cytometry, especially no evidence of residual leukemic cells.

CPT:88189

 

138. RIB LESION: 1% monoclonal plasma cells (numerous plasma cells in H&E)

Immunophenotyping of rib lesion biopsy by flow cytometry shows a T cell  population (about 62% of the cells gated), a small B cell population (about 9% of the cells gated), Plasma cells (gated with CD38) account for about 1% of all the cells analyzed and show cytoplasmic lambda light chain restriction. The plasma cells are positive for CD56. They are negative for CD19, and cytoplasmic kappa light chain.

Impression: presence of monoclonal plasma cells (1%) in rib lesion.  Examination of rib lesion touch preps and biopsy shows numerous plasma cells.  The small number of plasma cells in this flow cytometric analysis (compared to microscopic findings) is most likely due to sampling artifacts.

CPT:88187

 

139. BM: AML with aberrant expression of CD2, CD7

Immunophenotyping of peripheral leukocytes by flow cytometry shows a predominant myeloblast population that is positive for CD34, CD13, CD38, CD117, and HLA-DR.  They show aberrant expression of CD2 and CD7. These blasts are negative for MPO, CD33, CD3, CD4, CD8, CD5, CD14, CD16, CD56, CD19, CD20, CD10, CD64, and TdT. Impression: these findings are consistent with acute myeloid leukemia. The positive results for CD34 and HLA-DR do not support acute promyelocytic leukemia. Negative results for CD14, CD64, and CD4 do not support acute myelomonocytic leukemia.

CPT:88189

 

140. Soft tissue, mandible: artifactual loss of plasma cells (numerous plasma cells in H&E)

Flow cytometry analysis shows less than 0.5% of the cells from the sample expressing plasmacytic marker (CD38). The flow cytometry results are non-diagnostic due to the lack of sufficient plasma cells from the sample for analysis.  Morphological review of biopsy shows many plasma cells in tissue sections. The lack of sufficient plasma cells in this flow cytometry sample is likely due to technical artifacts (such as fragile plasma cells)

 

141. PB: CLL with pos ZAP70

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 93% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, surface kappa light chain restriction (dim signal). These B cells are negative for CD10, FMC7, and CD38. These B cells have small nuclear size (based on forward-scatter signal). Impression: Impression: these results, together morphological findings in peripheral blood, are consistent with chronic lymphocytic leukemia (CLL). Note: ZAP70 was sent to Quest Laboratory. The result (4/19/2011) showed 83% of the B cells with co-expression of ZAP70 and CD19. This positive finding of ZAP70 is associated with immunoglobulin VH unmutate genotype and adverse prognosis in this patient with CLL.

CPT:88189

 

142. Nasal mass; pos CD56, negative for NK/T lymphoma

Immunophenotyping of sinonasal mass biopsy by flow cytometry shows an abnormal population (20% of the cells analyzed) that is positive for CD56 and negative for all B cell markers and T cell markers. They are also negative for CD34.  Further analysis shows that these cells are negative for CD2 and cytoplasmic CD3. These cells have large nuclear size (based on forward-scatter signal). Impression: no immunophenotypes of lymphoma is found with flow cytometry, especially no evidence of NK/T cell lymphoma.  The abnormal CD56-positive population may represent non-hematopoietic tumors such as neuroblastoma.

CPT:88189                                                                                                                                           

 

143. Retroperitoneal mass: DLBCL, low cell viability

Immunophenotyping of retroperitoneal mass by flow cytometry shows a small T cell population (about 2% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a predominant B cell population (about 71% of the cells analyzed) that is negative for CD5, CD10, CD23, no expression of surface-light chains (neither kappa nor lambda). These B cells are positive for CD20, and partially positive for CD19. Impression: these results are  consistent with a B-cell lymphoma.  Even though the results are compromised by low cell viability (20%-80%), the diagnosis of diffuse large B cell lymphoma  is also supported by morphology and immunostains (please refer to report CA-8-190 for details).

CPT:88189

 

144. Pleural fluid: a small number of NK cells

Immunophenotyping of pleural fluid by flow cytometry shows a T cell population (about 63% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 1% of the cells analyzed), also a sub-population of NK cells that are positive for CD2, CD56 and CD16 (about 21% of the cells analyzed). Impression: no abnormal immunophenotypes are found with flow cytometry.

CPT:88188

 

145. Mediastinal mass: thymoma or thymic hyperplasia

Immunophenotyping of mediastinal mass biopsy by flow cytometry in gate #1 shows predominant a T cell population (about 84% of all the cells gated). They show expression of CD2, CD5, CD7, TdT, co-expression of CD4 and CD8. Analysis of cells in gate #2 shows a T cells population (about 98% of all the cells gated) that is positive for CD2, CD5, CD7, CD10, TdT with loss of CD3, CD4 and CD8. All the T cells have small nuclear size (based on forward-scatter signal). Smear pattern in scattergrams is observed for CD3, CD4, CD8, and TdT for cells in both gates. Impression: the results are most compatible with thymocytes (in either thymoma or thymic hyperplasia). They are not supportive of T lymphoblastic lymphoma.

CPT:88189

 

146. Right thigh mass biopsy: T cell/histiocyte-rich large B cell lymphoma (flow is non-diagnostic)

Immunophenotyping of right thigh mass biopsy by flow cytometry shows a large T cell population (about 95% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 6% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Most lymphocytes have small nuclear size (based on forward-scatter signal). Impression: no abnormal immunophenotypes are found with flow cytometry. Note that these results are not diagnostic for T cell/histiocyte-rich large B cell lymphoma in this patient due to the small number of malignant cells (less than 10% of the cells in the sample). Please refer to surgical pathology report HS-11-4252 for further details.

CPT:88189

 

147. Right tonsil biopsy: follicular hyperplasia (92% B lymphocytes)

Immunophenotyping of the right tonsil biopsy by flow cytometry in the large cell area (with high forward-scatter  signal) shows a small T cell population (about 8% of the cells gated), a prominent B cell population (about 92% of the cells gated) that is positive for CD19, CD20, CD22, CD10, and FMC7. They show no surface light-chain restriction.  Analysis of small lymphocytes with low forward-scatter signal (not shown) reveals similar marker profile as that of the large lymphocytes.  Impression: these immunophenotypic results are consistent with follicular lymphocytes (centroblasts and centrocytes) in reactive follicles of the tonsil. Please refer to UT Surgical Pathology report S11-1460 for further details).

CPT:88189

 

148. BM: no evidence of MDS

Immunophenotyping of bone marrow lymphocytes by flow cytometry shows a T cell population (about 77% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers except for a low CD4/CD8 ratio (0.15), most consistent with patient's history of HIV, a B cell population (about 12% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Analysis of the cells in the granulocytic area (not shown) demontrates that very few cells are with low side-scatter signals. Also, the granulocytes have normal signal distribution for CD13, CD33, CD16, and CD11b as seen in scattergrams for CD13/CD33, CD13/CD16 and CD11b/CD16 (no increase in CD13 or CD33 signal and no decrease in CD16 or CD11b signals). Also, CD10 is not decreased; CD56 and HLA-DR are not increased. These results for granulocytes show no evidence of myelodyplasia. Impression: no abnormal immunophenotypes are found with flow cytometry. Especially, no evidence of myelodysplasia is seen in granulocytes with flow cytometry.

CPT:88189

 

149.BM: suggestive of MDS

Immunophenotyping of bone marrow lymphocytes (Gate 1) by flow cytometry shows a T cell population (about 59% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 30% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Analysis of the cells in the granulocytic area (Gate 2) shows that there is a significant number of cells with low side-scatter signals. Also, the granulocytes show increase in CD13 signal and decrease in CD16 or CD11b signals as seen in scattergrams for CD13/CD16 and CD11b/CD16. Also, CD10 is decreased; CD56 and HLA-DR are increased. These results for granulocytes are suggestive of myelodyplasia.

Impression: abnormal immunophenotypic patterns of granulocytes are found with flow cytometry. These findings are suggestive of myelodysplasia.

CPT:88189

 

150. Supraclavicular lymph node biopsy: plasmablastic lymphoma

Immunophenotyping of supraclavicular lymph node biopsy by flow cytometry in gate #1 shows a T cell population (about 85% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 9% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction. Analysis of cells gated for CD38 positivity shows a significant cellular population that is positive for CD56 and negative for CD19. Cytoplasmic light-chain analysis of CD38-positive cells shows kappa light chain restriction. Analysis of cells in gate #2  (cells with large size based on forward-scatter signal) shows an abnormal cellular population that is positive for CD56 and negative for CD45, also negative for all T cell markers and B cell markers.

Impression: these results, together with morphological and immunostain findings in lymph node, are consistent with plasmablastic lymphoma (please refer to UT surgical report S11-xxx  for further details).

CPT:88189

 

151. BM: a subpopulation  of cells with low side-scatter signal but no evidence of MDS

Immunophenotyping of bone marrow lymphocytes (Gate 1) by flow cytometry shows a monocytic population population (about 15% of the cells analyzed) with expression of CD4, CD11b, CD13, and CD33.  Very few cells are seen in the lymphocytic gate (not shown). Analysis of the cells in the granulocytic area (Gate 2) shows that there is a subpopulation  of cells with low side-scatter signals. However, the granulocytes have normal signal distribution for CD13, CD16, and CD11b as seen in scattergrams for CD13/CD16 and CD11b/CD16 (no increase in CD13 signal and no decrease in CD16 or CD11b signals). Also, CD10 is not decreased; CD56 and HLA-DR are not increased.  These results for granulocytes show no evidence of myelodyplasia.

Impression: no abnormal immunophenotypes are found with flow cytometry. Especially, no evidence of myelodysplasia is seen in granulocytes with flow cytometry.

CPT:88189

 

152. BM: lymphoplasmacytic lymphoma

Immunophenotyping of bone marrow aspirate by flow cytometry shows an abnormal B cell population (about 88% of the cells analyzed) that is positive for CD19, CD20, CD22, HLA-DR, FMC7, surface kappa light chain restriction, also cytoplasmic kappa light chain restriction.  These B cells are negative for CD5, CD10, CD11c, and CD103. These B cells are predominantly small in size (based on forward-scatter signal). Analysis of CD38-positive cells shows a small abnormal plasma cell population. These plasma cells are partially positive for CD56, with cytoplasmic kappa light-chain restriction. They are negative for CD19. Impression: these flow cytometry results, together with morphological findings in bone marrow (diffuse lymphocytic infiltrates consisting of mature lymphocytes, some with plasmacytoid forms, admixed with plasma cells), are most consistent with lymphoplasmacytic lymphoma.

CPT:88189

 

153. LN: cHL (flow is not diagnostic)

Immunophenotyping of lymph node core biopsy by flow cytometry shows a T cell population (about 73% of the cells analyzed) with high CD4/CD8 ratio (6:1), otherwise no aberrant loss or aberrant expression of T cell markers, a B cell population (about 24% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction.  Impression: no abnormal immunophenotypes are found with flow cytometry. Note that classical Hodgkin lymphoma cannot be diagnosed with flow cytometry testing. Please refer to cytopathology report (CA-11-xxxx issued on 9/6/2011) for full details.

CPT:88189

 

154. BM: 20% hematogones in 15 y/o male with neuroblastoma

Immunophenotyping of bone marrow aspirate by flow cytometry shows a lymphocytic population (Gate #1) with normal immunophenotype. A sub-population of hematogones is found (Gates #2 and #3) which express CD45 (down-regulated), CD34, CD10 (bright signal intensity), CD19, CD20, CD38 (bright signal intensity), and TdT.  They are negative for CD99 and CD58. Scattergrams of CD34 and CD20 (CD20 paired with CD10) show a smear-out pattern of CD34 and CD20 indicating a continuum of maturation, consistent with that of hematogones.  The hematogones account for approximatedly 20% of the bone marrow cells. Note that hematogones may be increased in bone marrow of very young patients. Impression: presence of a sub-population of hematogenes in bone marrow; no evidence of hematologic malignancy.

CPT:88189

 

 

155. BM: AML with only 1% myeloblasts in aspirate due to dilution

Immunophenotyping of bone marrow aspirate (Gate 1) by flow cytometry shows a T cell population (about 89% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 4% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Analysis of the cells in the blast area (Gate 2) shows less than 1% of the leukocytes in peripheral blood with co-expression of CD34, CD13, CD33, and CD117.

Impression: a small number of myeloblasts is found bone marrow aspirate with flow cytometry. This is most likely due to suboptimal aspirate (peripheral blood contamination).  Bone marrow aspirate smear and biopsy show numerous myeloblasts. Please refer to bone marrow report HB-11-163 for full details.

CPT:88189

 

156. BM: No residual myeloblasts, CML with accelerated phase, s/p chemo

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #1 shows a T cell population (about 87% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (less than 1% of the cells analyzed). Analysis of cells in gate #2 (blast area) shows a small number of normal myeloblasts (<2%) that are positive for CD13, CD33, and negative for TdT. Impression: no residual myeloblasts are found with flow cytometry in this patient with history of CML in accelrated phase.

CPT:88189

 

157. BAL: low number of lymphocytes and a high H/S ratio

Immunophenotyping of the BAL sample by flow cytometry shows a T cell population (about 86% of the cells analyzed) with a high CD4/CD8 ratio (5.1), a small B cell population (less than 1% of the cells analyzed). Lymphocytes account for only 10% of the cells in the sample. Impression: small number of lymphocytes in BAL sample with a predominant CD4-pos cells.           

CPT:88187    

 

158. Very few leukocytes in sample

Flow cytometry analysis of lymph node sample shows less than 1% of the cells from the sample expressing leukocytic marker (CD45). They consist of a T cell population (about 83% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 15% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction. Impression: A small number of normal lymphocytes are detected with the flow cytometry. The remaining cells (99% of the sample cells) are not leukocytes. This may be seen in benign tissue or a non-lymphoma tumor. Clinical correlation is suggested.

CPT:88189

 

159. BM: NK/T Lymphoma

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell population (about 40% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers. Approximately 41% of the lymphocytes express a marker profile consistent with NK cell lineage (positive for CD2, CD56; and negative for CD3, CD7).  Impression: increased number of NK cells in bone marrow. This finding is consistent with lymphoma involvement in bone marrow of this patient with recent diagnosis of nasal NK/T cell lymphoma. Please refer to bone marrow report (HB-9-xx) for full details.

CPT:88189

 

160. BM:CMML-accelerated phase

Immunophenotyping of bone marrow leukocytes by flow cytometry gated in blast area shows a blast population that is positive for CD13, MPO, CD33, CD11b, CD4, CD117, and CD15. They are negative for CD34, CD14, CD64, CD56, CD19, CD10, and TdT. The blasts account for about 15% of bone marrow cells. Review of the aspirate smear shows 15% blasts, and 20% monocytes. Impression: the immunophenotyping results by flow cytometry, together with morphological findings, are most consistent with chronic myelomonocytic leukemia in accelerated phase.

CPT:88189

 

161. Spine lesion: plasma cell malignancy

Immunophenotyping of the spine lesion biopsy by flow cytometry shows a small lymphocytic population (2% of the analyzed cells) with normal marker profile for B cells and T cells. There is a predominant plasma cell population (about 85% of the cells analyzed) that is positive for CD38, cytoplasmic lambda light chain restriction. The plasma cells are negative for CD19, and CD56. Impression: presence of numerous monoclonal plasma cells (85%) in spine lesion. Examination of spine lesion  biopsy shows numerous plasma cells. The findings are consistent with a plasma cell malignancy. Please refer to surgical pathology report HS-12-xxxx  for full details.

CPT:88189

 

162. PB: aggressive NK cell leukemia vs. chronic NK cell lymphoproliferative disorder

Immunophenotyping of peripheral blood  leukocytes by flow cytometry shows a T cell  population (about 30% of the cells analyzed) with no aberrant loss or  aberrant expression of T cell markers, a B cell population (about 10% of the cells analyzed) that is negative for CD5, CD10, and no surface light-chain restriction. Approximately 60% of the lymphocytes express a marker profile consistent with NK cell lineage (positive for CD2, CD16, CD56; and negative for CD5, CD3, CD4, CD8, CD19, CD20, and other B cell markers). These NK cells account for about 30% of the peripheral blood leukocytes. Impression: increased number of NK cells in peripheral blood. This may represent aggressive NK cell leukemia or chronic NK cell lymphoproliferative disorder. Clinical correlation is suggested.

CPT 88189

 

 

163. PB: B lymphoblastic leukemia

Immunophenotyping of peripheral blood by flow cytometry shows predominant a B cell population (about 80% of all the cells analyzed).  These B cells have small nuclear size (based on forward-scatter signal) and show expression of CD10, CD19, CD38, HLA-DR, and TdT.  They are partially positive for CD20 and negative for CD2, CD3, CD4, CD8, CD5, CD7, CD56, CD34, CD13, CD117, and CD33. Review of peripheral blood smear shows a predominant lymphoblast population. Impression: the immunophenotype results and morphology are consistent with precursor B lymphoblastic leukemia. Dr. Rodriguez was notified of the findings on 2/11/09.

CPT:88189

 

164. Pelvic mass: B lymphoblastic lymphoma

Immunophenotyping of left pelvic mass by flow cytometry in gate#1 shows a T cell population (about 97% of the cells in gate#2) with no aberrant loss or aberrant expression of T cell markers, a small B cell population (about 2% of the cells analyzed).  A predominant lymphoblast population is seen in gate #2(approximately 87% of all the cells analyzed in gate #2). These B cells have small-intermediate nuclear size (based on forward-scatter signal) and show expression of CD34, CD10, CD19, CD38, HLA-DR, and TdT.  They show aberrant expression of CD13. They are partially positive for CD20 (23%) and negative for CD2, CD3, CD4, CD8, CD5, CD7, CD56, CD117, and MPO. Impression: the immunophenotype results are consistent with B lymphoblastic lymphoma.

CPT:88189

 

165. BM: Benign monoclonal lymphocytosis (BML)

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 59% of the cells gated) with no aberrant loss or aberrant expression of T cell markers, and a B cell population (35% of the cells gated). A small subpopulation of B cells (21% of the cells gated) is positive for CD5, CD19, CD20 and surface lambda light-chain restriction. They are negative for CD23. Gating of CD38 shows no evidence of monoclonal plasma cells. Impression: no monoclonal plasma cells are found with flow cytometry. This study also shows a small number of monoclonal B cell lymphocytes (1.7% of bone marrow cells) that is positive for CD5. This is most consistent with benign monoclonal lymphocytosis.

CPT:88189

 

166. BM: AML-M2 transformed to AML-M6

Immunophenotyping of bone marrow cells by flow cytometry in blast area shows a predominant early normoblast population that is negative for all T cell markers, B cell markers, CD13, CD33, CD34, CD64, MPO, CD117, Glycophoryn A and TdT. They are positive for CD71. They show down-regulated CD45. Analysis of cells with negative CD45 expression shows a mature normoblast population  with expression of glycophorin A and CD71. Impression: these findings, together with morphological findings in bone marrow (93% normoblasts), are consistent with acute erythroid leukemia (pure erytholeukemia). The immunophenotypes are different from leukemic cells in all previous bone marrows including the diagnostic bone marrow. Please refer to bone marrow report HB-13-147 for full details.

CPT:88189

 

167. BM: 2% hematogones, no residual APL

Immunophenotyping of bone marrow aspirate by flow cytometry shows less than 3% of total events  present in the CD45-dim, intermediate side scatter gate (Gate 1, the blast gate), with a subset positive for CD34/CD13, CD117/CD34. Another small different subset is positive for CD19/CD10, CD19/CD34 and CD10/CD34 in a spectrum of maturation. The HLA-DR expression is positive. Impression: Small population of events with immunophenotype consistent with hematogones (2% of bone marrow cells) and normal myeloblasts (1% of bone marrow cells). No evidence of residual APL cells is seen.

CPT:88189

 

168. BM: AML-M4 or M5

Immunophenotyping of peripheral blood leukocytes by flow cytometry in monocytic area (gate #2) shows a monocytic population (approximately 35% of nucleated cells). They are positive for CD13, CD4, CD33, CD38, CD56, CD11b, CD64, CD14, and HLA-DR. Analysis of cells in blast area (gate #1) shows a myeloblast population (approximately 33% of nucleated cells). They are positive for CD34, CD117, CD13, CD33, CD38, CD56, and HLA-DR. They are negative for MPO and TdT. Impression: these findings, together with the presence of numerous blasts and monocytes in the peripheral blood, are most consistent with acute myelomonocytic leukemia or acute monocytic leukemia (depending on cell count differential in bone marrow aspirate).

CPT:88189

 

169. CSF: Many B lymphoblasts, negative by flow, s/p chemo

Immunophenotyping of CSF by flow cytometry shows a predominant T cell population (99% of lymphocytes) with normal CD4/CD8 ratio, a small B cell population (1% of the cells analyzed). TdT is negative. The lymphocytes have small nuclear size (based on forward-scatter signal). Impression: no abnormal immunophenotypes are found with flow cytometry. Note: these findings are not diagnostic due to low viability of lymphoblasts in the sample (s/p intrathecal therapy). Morphological review of CSF still shows many lymphoblasts.

CPT:88189

 

170. PB:  T-LGL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows a T cell population (about 40% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population (about 20% of the cells analyzed) that is negative for CD5, CD10, no evidence of surface-light chain restriction.

Approximately 40% of the lymphocytes express a marker profile consistent with T-LGL cell lineage (positive for CD2, CD3, CD8; and negative for CD4, CD7).  Impression: This finding is consistent with T cell large granular lymphocytic leukemia.

CPT 88188                                                                                                                                                                                      

171. Mediastinal mass: high CD4/CD8 in cHL

Immunophenotyping of mediasinal mass core biopsy by flow cytometry shows a T cell population (about 85% of the cells analyzed) with high CD4/CD8 ratio (28:1), otherwise no aberrant loss or aberrant expression of T cell markers, a B cell population (about 12% of the cells analyzed) that is negative for CD5, CD10, no surface light-chain restriction. Impression: no abnormal immunophenotypes are found with flow cytometry. The high CD4/CD8 ratio is not specific but is often associated with classical Hodgkin lymphoma. Please refer to cytopathology report (CA-15-493) for full details.

 

172. Bone marrow: No MRD in AML, s/p Chemo

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #2 shows a T cell population with no aberrant loss or aberrant expression of T cell markers, a B cell population with no surface light chain restriction. Analysis of cells in gate #1 (blast area) shows a small number of normal myeloblasts (<2%) that are positive for CD13, CD33, and negative for CD4, CD14, CD64, CD56, and TdT. Review of medical records shows the original (diagnostic) flow cytometry results in Aug 2013: positivity for CD13, CD33, CD14, CD64, CD56, CD15, CD38, and  HLA-DR, and partial expression of CD4. Impression: no residual leukemic cells are found with flow cytometry in this patient with history of AML, s/p chemotherapy.

 

173. Bone marrow: 2% hematogones with 1.5% myeloblasts

Immunophenotyping of bone marrow aspirate by flow cytometry shows less than 4% of total events present in the CD45-dim, low side-scatter gate (Gate #2, the blast gate), with a subset of myeloblasts (1.5%) positive for CD34/CD13, and negative for CD64, CD4. Another small different subset of hematogones (2%) is positive for CD19/CD10, CD19/CD34 and CD10/CD34 in a spectrum of maturation. Previous leukemic profile is as following: positive for CD13, CD33, CD64, CD4; negative for CD34, CD117. Impression: small population of events with immunophenotype consistent with hematogones (2% of bone marrow cells) and normal myeloblasts (1.5% of bone marrow cells). No evidence of residual AML cells is seen.

 

174. Bone marrow: hairy cell leukemia

Immunophenotyping of bone marrow aspirate by flow cytometry with gating in the area with intermediate side-scatter signal shows an abnormal B cell population (about 94% of the cells gated) that is positive for CD19, CD20, CD22, FMC7, CD11c, CD103, CD25, surface kappa light-chain restriction. The signal for CD11c and CD22 are bright. These B cells are negative for CD5, CD10, and  CD23. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together morphological findings in bone marrow aspirate, are most consistent with hairy cell leukemia.

 

175. Lacrimal gland: mantle cell lymphoma

Immunophenotyping of lacrimal gland biopsy by flow cytometry shows an abnormal B cell population (about 82% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD22, FMC7, surface kappa light-chain restriction (bright signal). These B cells are negative for CD10, CD23, CD11c, CD103. These B cells have small-intermediate nuclear size (based on forward-scatter signal).

Impression: these results, together with morphology in lacrimal gland biopsy, are most consistent with mantle cell lymphoma. Cyclin D1 immunostain for the lymph node biopsy is positive for lymphoma cells (report HS-xxxx)

 

176. Lung biopsy: Reactive, low CD4 in HIV patient, aberrant loss of CD7

Immunophenotyping of LUL sample by flow cytometry shows an abnormal population of T lymphocytes.  These cells show expression of CD2, CD3, CD8, and CD5. They are negative for CD4 and also show aberrant loss of CD7. Impression: histological examination does not show evidence of lymphoma (report CN-15-600). Patient is HIV-positive with an expected low CD4 count and CD7 can be aberrantly lost in a reactive condition.

 

 

177. Pleural fluid: PEL

Immunophenotyping of pleural fluid by flow cytometry in gates #2 shows an abnormal population of cells (approximately 30% of the cells in the sample) shows positivity for CD45, and CD4. These cells are negative for other T cell markers (CD2, CD3, CD8, CD5, CD7) and B cell markers (CD19, CD20, CD22). They show neither surface nor cytoplasmic light chain restriction. The nuclear size is large based on forward-scatter signal. Review of pleural fluid sample shows many large lymphocytes with prominant nucleolie, and basophilc cytoplasm. Additional immunostains on cytology sample (cell block, report CN-15-810) show that the malignant cells are positive for CD30, CD43, CD4, Ki67 and negative for CD20, ALK1, CD138, CD79a, bcl1, TdT, bcl2, PAX5, CD10, CD2, CD8, CD5, CD7. HHV8 stain is positive.

Impression: these results, together with morphological findings, are most consistent primary effusion lymphoma.

 

178. Bone marrow: CD5-positive low grade leukemia/lymphoma

Immunophenotyping of bone marrow aspirate by flow cytometry shows an abnormal B cell population (about 96% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD22, surface kappa light chain restriction (bright signal). These B cells are negative for CD10, CD38, FMC7 and CD23. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results are most consistent with a CD5-positive low grade leukemia/lymphoma. Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) cannot be ruled out. However the following findings are not typical for CLL/SLL: negative CD23, and bright signal for CD20 and kappa ligh chain. Mantle cell lymphoma with leukemic presentation was ruled out with negative immunohistochemical stain for bcl1 on clot section.

 

179. PB: MCL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 38% of the cells gated) that is positive for CD5, CD19, CD20 (bright signal), CD22, FMC7, surface kappa light-chain restriction (bright signal). These B cells are negative for CD10, CD23, and CD11c. These B cells have small nuclear size (based on forward-scatter signal). Impression: these results, together with morphology in peripheral blood smear, are suggestive of mantle cell lymphoma with leukemic presentation. Further testing for t(11; 14) by PCR [IgH/bcl1] using peripheral blood is suggested (one purple-top tube). Findings were discussed with Dr. xxxx on 8/28/14.Note: bright signal of CD19/CD20/kappa light chain, together with negative CD23, positive FMC7 are not supportive of CLL/SLL.

 

180. BM: 7% polyclonal plasma cells

Immunophenotyping of bone marrow aspirate by flow cytometry shows a T cell population (about 81% of the cells analyzed) with no aberrant loss or aberrant expression of T cell markers, a B cell population that is negative for CD5, CD10, no surface light-chain restriction. Plasma cells account for less than 7% of the cells analyzed and show no evidence of cytoplasmic light chain restriction.

Impression: no evidence of monoclonal plasma cells by flow cytometry.

 

181. PB: CLL

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 95% of the cells analyzed) that is positive for CD5, CD19, CD20, CD22, CD23, surface lambda light chain restriction (dim signal). These B cells are negative for CD10, FMC7, and CD38. These B cells have small nuclear size (based on forward-scatter signal).

Impression: these results are most consistent with chronic lymphocytic leukemia (CLL).

 

182. PB: CD5-pos Lymphoproliferative Disorder

Immunophenotyping of peripheral blood leukocytes by flow cytometry shows an abnormal B cell population (about 82% of the cells analyzed) that is positive for CD5, CD19, CD20 (bright signal), CD22, CD23, CD38, FMC7, surface lambda light chain restriction (bright signal), and negative for CD10.

Impression: The immunophenotypical results are compatible with a CD5 positive B-cell proliferativediscorder. Note that the expression of FMC7 and bright CD19/CD20/lambda signals are atypical for a diagnosis of  chronic lymphocytic leukemia (CLL), therefore, mantle cell lymphoma which typically has expression of FMC7 and bright CD19/CD20/lambda signals can not be ruled out.  Bone marrow aspirate/biopsy is suggested for a definitive diagnosis if clinically indicated.

 

183. LN: non-hematopoietic tumor

Flow cytometry analysis shows almost all the cells from the sample lacking leukocytic marker (CD45). Gating cells with large nuclei (based on forward-scatter signal) shows that the large cells are negative for all B cell markers, T cell markers, and myeloid markers.

Impression: the flow cytometry results indicate that the tumor is of non-hematopoietic origin (please refer to surgical pathology report HS-15-12144 for details).

 

184. Mediastinal mass: T lymphoblastic lymphoma

Immunophenotyping of anterior mediastinal mass biopsy by flow cytometry shows predominant a T cell population (about 99% of all the cells analyzed). These T cells have small-intermediate nuclear size (based on forward-scatter signal) and show expression of CD2, CD5, CD7, co-expression of CD4 and CD8. They are negative for CD3, CD10, CD19, CD20, and TdT. No smear-out pattern is observed for CD4 and CD8 which rules out thymocytes.

Impression: the immunophenotype results and morphology are consistent with T lymphoblastic lymphoma.

Note that immunohistochemical stains on biopsy show positive CD3 and focal positivive TdT in the lymphoma cells. This discrepancy is most likely due to difference in sensitivity between antibodies used in the two methods. Pan-Keratin stain is also negative ruling out presence of epithelial cells in the sample.

 

185. BM: refractory anemia with excess blasts-type I (RAEB-I)

Immunophenotyping of bone marrow aspirate by flow cytometry in gate #2 shows a normal lymphocytic population (B cell and T cells). Analysis of cells in gate#1 (blast area) shows a myeloblast population that is positive for CD34, CD13, CD33 (partial), CD117, CD38, MPO (partial), and HLA-DR. These blasts are negative for CD41a, CD61, CD4, CD14, CD56, CD19, CD10, and TdT.  Impression: The flow cytometry results, together with myeloblast count of 8% in bone marrow, are consistent with refractory anemia with excess blasts-type I (RAEB-I)

 

186. BM: T-Cell LGL

Immunophenotyping of bone marrow leukocytes by flow cytometry shows a T cell population (about 99% of the cells in lymphocytic gate) with a marker profile consistent with T-LGL cell lineage (positive for CD2, CD3, CD8, CD7, CD57; and negative for CD4, CD56). The B cells account for less than 1% of the lymphocytes gated.

Impression: This finding, together with morphology in bone marrow, are consistent with T-cell large granular lymphocytic leukemia.

 

187. BM: Residual B lymphoblastic leukemia (8% leukemic cells)

Immunophenotyping of bone marrow leukocytes by flow cytometry in gate #2 shows a mixture of normal T lymphocytes and B lymphocytes. Analysis of cells in gate #1 (blast area) shows an abnormal B cell population (about 8% of all the bone marrow cells analyzed). These B cells show expression CD10, CD19, CD38, CD34, and TdT. They are partially positive for CD13, CD4 and negative for CD117, MPO, and CD33. This marker profile is found to be similar to that of previous diagnostic sample which in particular, showed partial expression of CD4 and CD13. Note that the lack of smear-out pattern of markers rule out the presence of hematogones in the bone marrow. There is also a subpopulation of normal myeloblasts (about 2% of all the bone marrow cells analyzed) with expresion of MPO, CD13, CD33, and CD117 (likely to be associated with recent Nupogen treatment).

Impression: the immunophenotype results are consistent with residual disease (8% of leukemic cells in this patient with B lymphoblastic leukemia, S/P chemotherapy).